<SEC-DOCUMENT>0001193125-20-292209.txt : 20201113
<SEC-HEADER>0001193125-20-292209.hdr.sgml : 20201113
<ACCEPTANCE-DATETIME>20201113063117
ACCESSION NUMBER:		0001193125-20-292209
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201113
DATE AS OF CHANGE:		20201113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Benitec Biopharma Inc.
		CENTRAL INDEX KEY:			0001808898
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39267
		FILM NUMBER:		201309103

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 14, 114 WILLIAM ST
		CITY:			MELBOURNE, VIC
		STATE:			C3
		ZIP:			3000
		BUSINESS PHONE:		61(0)3 8692-7222

	MAIL ADDRESS:	
		STREET 1:		LEVEL 14, 114 WILLIAM ST
		CITY:			MELBOURNE, VIC
		STATE:			C3
		ZIP:			3000
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d943701d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended September&nbsp;30, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U> </U><U></U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-39267</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">84-462-0206</FONT></FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3940 Trust Way, Hayward, California 94545 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices&nbsp;&amp; zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">780-0819</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, par value $0.0001</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BNTC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by
Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past
90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Large&nbsp;accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9744;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accelerated&nbsp;filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9744;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Smaller&nbsp;reporting&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9746;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emerging&nbsp;growth&nbsp;company</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#9746;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744; or &nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had 4,405,469 shares of
our common stock outstanding as of the close of business on November&nbsp;9, 2020. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BENITEC BIOPHARMA INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="toc"></A>INDEX TO FORM <FONT STYLE="white-space:nowrap">10-Q</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin943701_1">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS </A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin943701_2">PART <FONT STYLE="white-space:nowrap">I-FINANCIAL</FONT> INFORMATION
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Financial Statements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_4">Consolidated Balance Sheets as of September&nbsp;30, 2020 (Unaudited) and June&nbsp;30, 2020</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">F-2</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_5">Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended September&nbsp;30,<BR>2020 and 2019 (Unaudited)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">F-3</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_6">Consolidated Statements of Stockholders&#146; Equity for the Three Months Ended September&nbsp;30, 2020 and 2019<BR>(Unaudited)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">F-4</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_7">Consolidated Statements of Cash Flow for the Three Months Ended September&nbsp;30, 2020 and 2019 (Unaudited)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">F-5</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_8">Notes to Consolidated Financial Statements (Unaudited)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right">F-6</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_10">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_11">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin943701_12">PART <FONT STYLE="white-space:nowrap">II-OTHER</FONT> INFORMATION
 </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_13">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_14">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_15">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_16">Defaults Upon Senior Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_17">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_18">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ITEM 6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#fin943701_19">Exhibits</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin943701_20">SIGNATURES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">II-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_1"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Report contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control.
All statements, other than statements of historical fact included in this Report, regarding our strategy, future operations, financial position, projected costs, prospects, plans and objectives of management are forward-looking statements. When used
in this Report, the words &#147;could,&#148; &#147;believe,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;continue,&#148; &#147;predict,&#148; &#147;potential,&#148;
&#147;project,&#148; or the negative of these terms, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These statements involve known and unknown
risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These
risks, uncertainties and factors include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our plans to develop and potentially commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation and completion of preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and sufficiency of patient enrollment and dosing in any future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the availability of data from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and outcome of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated delays; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales, marketing, manufacturing and distribution requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market competition and the acceptance of our products in the marketplace; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of novel AAV vectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the plans of licensees of our technology; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical utility and potential attributes and benefits of ddRNAi and our product candidates,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">including the potential duration of treatment effects and the potential for a &#147;one shot&#148; cure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on our relationships with collaborators and other third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses, ongoing losses, future revenue, capital needs and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time over which we expect our cash and cash equivalents to be sufficient to execute on our business
plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and the duration of our patent portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of local, regional, and national and international economic conditions and events; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">current&nbsp;COVID-19&nbsp;pandemic,</FONT> the disease caused
by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;SARS-CoV-2&nbsp;virus,</FONT></FONT> which may adversely impact our business and preclinical and future clinical trials; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as well as other risks detailed under the caption &#147;Risk Factors&#148; in this Report and in other reports filed with the SEC. Although we believe that we
have a reasonable basis for each forward-looking statement contained in this Report, we caution you that these statements are based on a combination of facts and important factors currently known by us and our expectations of the future, about which
we cannot be certain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based the forward-looking statements included in this Report on information available to us on the date of
this Report or on the date thereof. Except as required by law we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised to consult any
additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;quarterly</FONT> reports <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;and</FONT> current reports <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All forward-looking statements included herein or in documents incorporated herein by reference are expressly qualified in their entirety by
the cautionary statements contained or referred to elsewhere in this Report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_2"></A>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FINANCIAL INFORMATION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_4"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except par value and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Stockholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities, less current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value&#151;10,000,000 shares authorized; 1,108,374 shares issued and
outstanding at September&nbsp;30, 2020 and June&nbsp;30, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_5"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties and license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,690</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (loss), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (loss), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign currency translation gain (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,451</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">858,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_6"></A>Consolidated Statements of Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;127,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock sold for cash, net of offering costs of $240</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of <FONT STYLE="white-space:nowrap">pre-purchased</FONT> warrants, net of transactions
costs of $240</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,043,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(109,956</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,168</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(116,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,108,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(119,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_7"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issues of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share issue transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;16,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial measurement of operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_8"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. (the &#147;Company&#148;) is a corporation formed under the laws of Delaware, United States, on November&nbsp;22, 2019.
Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#147;BBL&#148;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian
Securities Exchange, or ASX, from 1997 until April&nbsp;15, 2020. On August&nbsp;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#146;s business focuses on the
development of novel genetic medicines. Our proprietary platform, called <FONT STYLE="white-space:nowrap">DNA-directed</FONT> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate
sustained silencing of disease-causing genes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;27, 2019, BBL announced its intention to
<FONT STYLE="white-space:nowrap">re-domicile</FONT> from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the <FONT
STYLE="white-space:nowrap">re-domiciliation,</FONT> acquired all BBL shares and BBL became a wholly-owned subsidiary of Benitec Biopharma Inc. BBL shareholders received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL&#146;s
American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company&#146;s common stock for every three ADSs held. The <FONT STYLE="white-space:nowrap">re-domiciliation</FONT> was completed on
April&nbsp;15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March&nbsp;26, 2020 and by the Supreme Court of Queensland on March&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the U.S. Securities and Exchange Commission&#146;s (&#147;SEC&#148;) Staff Accounting Bulletin Topic 4C, all issued and
outstanding shares of the Company&#146;s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BBL announced that the transaction to redomicile from Australia to the United States was fully implemented on April&nbsp;15, 2020. The <FONT
STYLE="white-space:nowrap">re-domiciliation</FONT> was approved by BBL shareholders at a Scheme Meeting held on March&nbsp;26, 2020 and confirmed by the Supreme Court of Queensland on March&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms used in refer (i), prior to the <FONT
STYLE="white-space:nowrap">re-domiciliation</FONT> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <FONT STYLE="white-space:nowrap">re-domiciliation,</FONT> to Benitec Biopharma Inc., a Delaware corporation, and its
subsidiaries (including BBL). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc. is listed on the Nasdaq Capital Market LLC (&#147;Nasdaq&#148;) under the symbol
&#147;BNTC&#148;, and Benitec Biopharma Inc. is subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BBL became a wholly owned subsidiary of Benitec Biopharma Inc. and delisted from the ASX on April&nbsp;15, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s fiscal year end is June 30. References to a particular &#147;fiscal year&#148; are to our fiscal year end June&nbsp;30 of
that calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of
Benitec Biopharma Inc. and its wholly owned subsidiaries: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Principal&nbsp;place<BR>of</I></B><br><B><I>business/country<BR>of incorporation</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Ownership<BR>Fiscal<BR>Year 2020</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><I>Ownership<BR>Fiscal<BR>Year 2019</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Proprietary Limited (&#147;BBL&#148;)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Australia</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Australia Proprietary Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Australia</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">United<BR>Kingdom</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">USA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benitec LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">USA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RNAi Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">USA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tacere Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">USA</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of Presentation
and Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation and Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements contained in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
have been prepared in accordance with generally accepted accounting principles in the U.S. (&#147;GAAP&#148;)&nbsp;for interim financial information and with the instructions to Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Article 10 of SEC
Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal
recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in
conjunction with the Company&#146;s audited financial statements and accompanying notes included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#146;s consolidated financial statements requires management to make estimates and assumptions that impact the
reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the
Company&#146;s consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax
assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to
be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may
differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#146;s future results of operations will be affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is frequently made herein to the Financial Accounting Standards Board (the &#147;FASB&#148;) Accounting Standards Codification
(&#147;ASC&#148;). This is the source of authoritative US&nbsp;GAAP recognized by the FASB to be applied to <FONT STYLE="white-space:nowrap">non-governmental</FONT> entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements include the Company&#146;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Reporting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance.
The Company views its operations and manages its business in one operating segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency Translation and Other Comprehensive Income
(Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s functional currency and reporting currency is the United States dollar. BBL&#146;s functional currency
is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at
the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising
from the use of different exchange rates from period to period are included as a component of stockholders&#146; equity as &#147;Accumulated other comprehensive income (loss).&#148; Gains and losses resulting from foreign currency transactions are
included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures its financial assets and liabilities in accordance with US&nbsp;GAAP using ASC 820, <I>Fair Value
Measurements.</I> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair
value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation
techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three levels: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&nbsp;1:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&nbsp;2:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted
prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="8%" VALIGN="top" ALIGN="left">Level&nbsp;3:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unobservable inputs in which little or no market data exists, therefore developed using estimates and
assumptions developed by us, which reflect those that a market participant would use. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the
Company&#146;s cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of September&nbsp;30, 2020, and
June&nbsp;30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less
with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has
not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade and Other
Receivables </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a
determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <FONT STYLE="white-space:nowrap">write-off</FONT> experience.
The Company&#146;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property
and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for
maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed
from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Software</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-4</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lab equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-7</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Furniture and fixtures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-7</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Computer hardware</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">3-5</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Leasehold improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shorter of the lease term or estimated useful lives</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying
amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the
asset&#146;s expected future discounted cash flows or market value, if readily determinable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade and other payables </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to
their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The
Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that
the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease
commencement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After lease commencement, the Company measures its leases as follows: (i)&nbsp;the lease liability based on the
present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&nbsp;the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> lease asset based on the
remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and
any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basic and Diluted Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding
during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are
considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net
income (loss) per share when their effect is anti-dilutive. As of September&nbsp;30, 2020, and 2019, there were 145,421 and 65,852 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share
because their effect was anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASC 606 &#150; <I>Revenue from Contracts with Customers </I>(&#147;ASC 606&#148;) on July&nbsp;1, 2018. The
adoption of ASC 606 did not have a material impact on the consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon adoption of ASC 606, the Company
recognizes revenue in accordance with that core principle by applying the following steps: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a
customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management
considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the
contract was within the scope of ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of associated
<FONT STYLE="white-space:nowrap">know-how</FONT> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from
each other. Judgements were made in relation to the transfer of the license and <FONT STYLE="white-space:nowrap">know-how</FONT> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to
the point at which the transfer of <FONT STYLE="white-space:nowrap">know-how</FONT> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining
benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing revenues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflects the transfer of a right to use the intellectual property as it
exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a
significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these
amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated
balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflect a right to use the intellectual property as it exists at the point
in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#146;s subsequent sales of product occurs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Services revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is earned
(constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision
of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Research and
Development Grants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government grants are recognized at fair value where there is reasonable assurance that the grant will be
received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant income is generated through the Australian federal government&#146;s Research and Development Tax Incentive program, under which the
government provides a cash refund for the 43.5% of eligible research and development expenditures. This grant is available for the Company&#146;s research and development activities in Australia, as well as activities in the United States to the
extent such U.S.-based expenses relate to the Company&#146;s activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be
made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will not be claiming the Australian Government research and development grants going forward. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and
development expenses relate primarily to the cost of conducting clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials. Pre-clinical and clinical development costs are a significant component of research and development expenses.
Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are
based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by
the clinical trial partners. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records share-based compensation in accordance with ASC 718, <I>Stock Compensation</I>. ASC 718 requires the fair value of all
share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based
compensation at fair value using the Black-Scholes Option Pricing Model.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted FASB Accounting Standard Update
(&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2018-07</FONT> and accounts for <FONT STYLE="white-space:nowrap">non-employee</FONT> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair
value of such awards over the service period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 <I>Accounting for Income Taxes</I>, when
accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial
statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income.
Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
uncertain tax positions that meet a &#147;more likely than not&#148; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#146;s practice is to recognize interest and
penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13:</FONT> <I>Financial Instruments &#150; Credit Losses</I>
(Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#146;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized
only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after
December&nbsp;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#147;SRC&#148;) as of November&nbsp;15, 2019. As such, ASU <FONT STYLE="white-space:nowrap">2019-10:</FONT> <I>Financial
Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</I> amended the effective date for the Company to be for reporting periods beginning after December&nbsp;15, 2022. The Company will adopt this ASU effective July&nbsp;1,
2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements have been prepared in conformity with US&nbsp;GAAP, which contemplate continuation of the Company as a going concern. For the three months ended September&nbsp;30, 2020, and 2019, the Company incurred a
net loss of $2.7&nbsp;million and&nbsp;$1.1&nbsp;million, and used net cash of $2.3&nbsp;million and $0.5&nbsp;million in operations, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the existing cash and cash equivalents of the Company, including the proceeds from a public offering of common stock (and common
stock equivalents) that closed on October&nbsp;6, 2020 (see Note 13), management estimates that cash and cash equivalents will be sufficient to fund the Company&#146;s operations for at least the next twelve months from the filing of this
form&nbsp;10-Q. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial report does not contain any adjustments to the amounts or classifications of recorded assets or liabilities
that might be necessary if the Company does not continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements take no account of the
consequences, if any, of the effects of unsuccessful product development or commercialization, nor of the inability of the Company to obtain adequate funding in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Revenue </B>(US$&#146;000) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three Months Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Revenues from customers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licensing revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">* On July&nbsp;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The
agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#146;s product <FONT STYLE="white-space:nowrap">BB-301,</FONT> which was designed for the potential treatment of
Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company&#146;s intellectual property related to <FONT STYLE="white-space:nowrap">BB-301</FONT> and the transfer of the right to use the intellectual property of the Company&#146;s
<FONT STYLE="white-space:nowrap">BB-301</FONT> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&nbsp;6, 2019, we announced the termination
of the agreement with Axovant. The termination of the agreement was effective as of September&nbsp;3, 2019. The termination discharges all future performance obligations at termination date under the contract. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Disaggregated revenue&nbsp;(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended September&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Licensing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Royalties</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Development&nbsp;activities</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred at a point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Disaggregated revenue&nbsp;(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended September&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Licensing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Royalties</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Development&nbsp;activities</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred at a point in time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Services transferred over time</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Cash and Cash equivalents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash at Bank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BENITEC BIOPHARMA INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Other assets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Market value of listed shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Property and equipment, net </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(796</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense was $45,000 and $51,000 for the three months ended September&nbsp;30, 2020 and 2019,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Trade and other payables </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay
utilities, insurance, taxes and other operating expenses. The Company&#146;s lease does not contain any residual value guarantees or material restrictive covenants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, the Company&#146;s operating lease has a remaining lease term of 1.7 years and a discount rate of 4.67%. The
maturities of the operating lease liabilities are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">(US$&#146;000)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,&nbsp;2020</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded lease liabilities and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#146;s incremental
borrowing rate. Rent expense under the lease $52,000 for both the three months ended September&nbsp;30, 2020 and 2019, respectively, and was recorded in the general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Stockholders&#146; equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity
related to warrants during for the three months ended&nbsp;September 30, 2020,&nbsp;is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Common<BR>Stock&nbsp;from<BR>Warrants</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted-<BR>average<BR>Exercise<BR>Price&nbsp;(per&nbsp;share)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at July&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,326</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding and exercisable at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Employee Share Option Plan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the <FONT STYLE="white-space:nowrap">re-domiciliation,</FONT> the Company assumed BBL&#146;s obligations with respect to the settlement
of options that were issued by BBL prior to the <FONT STYLE="white-space:nowrap">re-domiciliation</FONT> pursuant to the Benitec Officers&#146; and Employees&#146; Share Option Plan (the &#147;Plan&#148;). This includes the Company&#146;s assumption
of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting
or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies,
retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the
<FONT STYLE="white-space:nowrap">re-domiciliation,</FONT> no new options have been or will be issued under the Plan. Current options on issue are under the BBL plan. From time to time, BBL issued employee&#146;s options to acquire shares in the
Company at a fixed price. Each option when exercised entitles the option holder to one share of common stock of the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable
except on death of the option holder. Employee options vest one third on each anniversary for three years. If an employee leaves the Company, they have 90 days to exercise their options or the options are cancelled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Equity Awards </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
activity related to equity awards, which comprised of stock options during the&nbsp;three months&nbsp;ended September&nbsp;30, 2020,&nbsp;is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Stock<BR>Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted-<BR>average<BR>Exercise<BR>Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>Remaining<BR>Contractual&nbsp;Term</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Intrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.89&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">68.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Share-Based Compensation Expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The classification of share-based compensation expense for the three months ended: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Three&nbsp;Months&nbsp;Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(US$&#146;000)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&nbsp;September 30, 2020, there was $119,000 of unrecognized share-based compensation expense related to
stock options issued under the Share Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended September&nbsp;30, 2020, and 2019, the Company did not recognize a provision or benefit for income taxes as it has
incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is more likely than not that the benefit will be realized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Commitments and contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contract commitments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for
termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Contingencies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time
to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Subsequent events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;6,
2020, the Company announced the closing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $3.10 per share. The Company also announced that the
underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the offering price. The total offering of 3,709,676 shares of common stock and common stock equivalents consisted of 2,666,644 firm
shares of common stock, 483,870 shares of common stock purchased under the underwriter&#146;s over-allotment options and 559,162 shares of common stock underlying <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants initially purchased for
$3.09 per share and immediately exercisable at $0.01 per share. The Company received gross proceeds of approximately $11.5&nbsp;million and net proceeds of approximately $9.9&nbsp;million from the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus
<FONT STYLE="white-space:nowrap">COVID-19</FONT> <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company
did experience some disruption from <FONT STYLE="white-space:nowrap">COVID-19</FONT> including disruption of the timing and completion of certain <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials we are unable to predict the overall impact
that <FONT STYLE="white-space:nowrap">COVID-19</FONT> will have on our financial position and operating results due to numerous uncertainties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_9"></A>Item&nbsp;2. Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of financial condition and operating results together with our consolidated financial statements and
the related notes and other financial information included elsewhere in this document. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet
medical needs via the application of the silence and replace approach to the treatment of genetic disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Benitec Biopharma Inc.
(&#147;Benitec&#148; or the &#147;Company&#148; or in the third person, &#147;we&#148; or &#147;our&#148;) is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in&nbsp;Hayward,
California. The proprietary platform, <FONT STYLE="white-space:nowrap">called&nbsp;DNA-directed&nbsp;RNA</FONT> interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of
disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">BB-301&nbsp;is</FONT> the most advanced ddRNAi-based genetic medicine currently under development by <FONT
STYLE="white-space:nowrap">Benitec.&nbsp;BB-301&nbsp;is</FONT> an internally <FONT STYLE="white-space:nowrap">optimized,&nbsp;AAV-based&nbsp;gene</FONT> therapy agent that is designed to both silence the expression of mutated, disease-causing genes
(to slow, or halt, the underlying mechanism of disease progression) and replace the mutant genes with normal, &#147;wild type&#148; genes (to drive restoration of function in diseased cells).&nbsp;This fundamental approach to disease management is
called &#147;silence and replace&#148; and this biological mechanism offers the potential to restore the underlying physiology of the treated tissues and, in the process, improve treatment outcomes for patients suffering from the chronic and,
potentially, fatal effects of Oculopharyngeal Muscular Dystrophy <FONT STYLE="white-space:nowrap">(OPMD).&nbsp;BB-301&nbsp;has</FONT> been granted Orphan Drug Designation in&nbsp;the United States&nbsp;and the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the combination of the targeted gene silencing effects of RNAi and the durable transgene expression achievable via the use of modified
viral vectors, the silence and replace approach has the potential to produce long-term silencing of disease-causing genes along with simultaneous replacement of wild type gene function following a single administration of the proprietary genetic
medicine. We believe this novel attribute of the investigational agents under development by Benitec may facilitate the achievement of robust clinical activity while greatly reducing the dosing frequencies traditionally expected for medicines
employed for the management of chronic diseases.&nbsp;Additionally, the establishment of chronic gene silencing and gene replacement may significantly reduce the risk of <FONT STYLE="white-space:nowrap">patient&nbsp;non-compliance&nbsp;during</FONT>
the course of medical management of potentially fatal clinical disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all dollar amounts in this section
are provided in thousands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2020, (the &#147;Implementation Date&#148;), <FONT STYLE="white-space:nowrap">the&nbsp;re-domiciliation&nbsp;of</FONT>
Benitec Limited (the <FONT STYLE="white-space:nowrap">&#147;Re-domiciliation&#148;),</FONT> a public company incorporated under the laws of the State of Western Australia, or Benitec Limited, was completed in accordance with the Scheme
Implementation Agreement, as amended and restated as of January&nbsp;30, 2020, between Benitec Limited and us. As a result of <FONT STYLE="white-space:nowrap">the&nbsp;Re-domiciliation,&nbsp;the</FONT> jurisdiction of incorporation was changed from
Australia to Delaware, and Benitec Limited became our wholly owned subsidiary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">The&nbsp;Re-domiciliation&nbsp;was</FONT> effected pursuant to a statutory scheme of arrangement under
Australian law, or the Scheme, whereby on the Implementation Date, all of the issued and outstanding ordinary shares of Benitec Limited were exchanged for newly issued shares of our common stock, on the basis of one share of our common stock, par
value $0.0001 per share, for every 300 ordinary shares of Benitec Limited issued and outstanding. Holders of Benitec Limited&#146;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of our
common stock for every three ADSs held. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">COVID-19</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, an outbreak of a novel strain of coronavirus was identified in Wuhan, China. This virus continues to spread globally, has
been declared a pandemic by the World Health Organization and has spread to nearly every country, including Australia and the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society,
which has resulted in and will likely continue to result in significant disruptions to businesses and capital markets around the world. The extent to which the coronavirus impacts us will depend on future developments, which are highly uncertain and
cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our research and development efforts are conducted globally, including the ongoing development of our silence and replace
therapeutic for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), and will be dependent upon our ability to initiate preclinical and clinical studies despite the
<FONT STYLE="white-space:nowrap">ongoing&nbsp;COVID-19&nbsp;pandemic.</FONT><B></B>&nbsp;As we continue to actively advance our preclinical programs, including our ongoing tissue transduction studies
<FONT STYLE="white-space:nowrap">for&nbsp;BB-301,&nbsp;we</FONT> are in close contact with our principal investigators and preclinical trial sites, which are primarily located in the France, and are assessing the impact <FONT
STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;on</FONT> our studies and the expected development timelines and costs of all of our product candidates, on an ongoing basis. In light of recent developments relating to
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;global</FONT> pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#146;s updated industry guidance for conducting clinical trials issued
on March&nbsp;18, 2020, we have experienced delays to the original timeline regarding the initiation and anticipated completion of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ongoing&nbsp;BB-301&nbsp;IND-enabling&nbsp;development</FONT></FONT> work. The initiation of <FONT STYLE="white-space:nowrap">the&nbsp;BB-301&nbsp;tissue</FONT> transduction study,
which represents a key component of <FONT STYLE="white-space:nowrap">the&nbsp;IND-enabling&nbsp;work,</FONT> was delayed by several months, however, the study has been recently initiated and the dosing of the initial preclinical cohorts has
proceeded without incident. We will continue to evaluate the impact of <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> on our business and expect to reevaluate the timing of our anticipated preclinical and clinical milestones
as we learn more and the impact <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;on</FONT> our industry becomes more clear. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had
also implemented work-from-home measures for the majority of our employees between March 2020 and September 2020, resulting in a reduction of laboratory work and a halt <FONT STYLE="white-space:nowrap">of&nbsp;non-essential&nbsp;business</FONT>
travel. As we transition our employees back to our premises, there is a risk <FONT STYLE="white-space:nowrap">that&nbsp;COVID-19&nbsp;infections</FONT> occur at our offices or laboratory facilities and significantly affect our operations.
Additionally, if any of our critical vendors are impacted, our business could be affected if we become unable to timely procure essential equipment, supplies or services in adequate quantities and at acceptable prices. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Nonclinical Programs </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nonclinical research efforts supporting the development of ddRNAi-based therapeutic agents and silence and replace-based therapeutic agents
targeting the treatment of Chronic Hepatitis B Virus Infection (&#147;HBV&#148;) and <FONT STYLE="white-space:nowrap">Age-Related</FONT> Macular Degeneration (&#147;AMD&#148;) have concluded and are no longer being continued by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Workforce Reduction </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;31,
2019, Benitec announced the completion of a workforce reduction of approximately 50%. Through this streamlining of operations, the Company retained staff members who are key to the achievement of the core research and development goals. The
rationalization of resources was deemed to be supportive of an extended financial runway for the Company while allowing Benitec to continue to advance the <FONT STYLE="white-space:nowrap">BB-301</FONT> program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Royalties, milestone payments and other license fees </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to pay royalties, milestone payments and other license fees in connection with our licensing of intellectual property from
third parties, including as discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into an exclusive sublicense agreement with NantWorks, LLC,
pursuant to which we agreed to make certain milestone and royalty payments, as well as periodic payments for so long as the agreement remained in effect. In December of 2018, the Company accrued a milestone payment of USD 300,000 (AUD 425,411),
which was anticipated to be paid to NantWorks, LLC under the sublicense agreement. It was later determined that the milestone was not required to be paid and, therefore, the accrual was reversed in December of 2019. We terminated the exclusive
sublicense agreement for convenience, with the termination effective as of June 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have collaborated with Biomics Biotechnologies
Co., Ltd., or Biomics, pursuant to several collaboration agreements in relation to single-stranded RNA and shRNA sequences for treatment of hepatitis B. In July 2015, we entered into
<FONT STYLE="white-space:nowrap">an&nbsp;earn-out&nbsp;agreement</FONT> with Biomics which confirmed Benitec&#146;s ownership of certain patents resulting from the collaboration in exchange for an upfront payment and equity issuance to Biomics and a
share of certain future licensing revenue received by Benitec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Foreign Currency Translation and Other Comprehensive Income (Loss) </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s functional currency and reporting currency is the United States dollar. BBL&#146;s functional currency is the Australian
dollar (AUD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are
translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#146; equity as &#147;Accumulated other
comprehensive income (loss).&#148; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss) for all periods presented includes only foreign currency translation gains (losses). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past Benitec
Limited has generated revenue from its operations through two activities: revenue from customers and revenue from government research and development grants. In the fiscal year ended June&nbsp;30, 2020, the Company generated funds primarily from
capital raising activities. For the three-month period ended September&nbsp;30, 2020, the Company received $55 in revenue relating to licensing fees. The Company has not generated any revenues from the sales of products. Revenues from licensing fees
are included in the revenue from customers line item on our statements of operations and comprehensive income (loss). The Research and Development Tax Incentive is recognized as Government research and development grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our licensing fees have been generated through the licensing of our ddRNAi technology to biopharmaceutical companies, and in the fiscal
year-ended June&nbsp;30, 2019, revenue was generated through a License and Collaboration Agreement with Axovant Sciences (the &#147;Axovant Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of our revenues for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three&nbsp;Months&nbsp;Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenues:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues from customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenues from customers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2018, the Company entered into the Axovant Agreement. The Axovant Agreement granted Axovant Sciences an exclusive worldwide
license to develop, manufacture, and commercialize products containing the Company&#146;s product known <FONT STYLE="white-space:nowrap">as&nbsp;BB-301,&nbsp;which</FONT> was designed for the potential treatment of Oculopharyngeal Muscular
Dystrophy. Service revenue consists of payments for services provided to Axovant Sciences pursuant to the Axovant Agreement. On June&nbsp;6, 2019, the termination of the Axovant Agreement was announced. The termination of the Axovant Agreement was
effective as of September&nbsp;3, 2019. The termination discharges all future performance obligations under the contract at the termination date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2020, the Company recognized $55 in customer revenues, as compared to $33 for the comparable
year ended September&nbsp;30, 2019. The increase in revenues from customers is due to the increase in licensing revenues in the current period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses relate primarily to the cost of conducting clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
trials. Pre-clinical and clinical development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been
performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time
before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, related benefits, travel, and equity-based compensation expense. General
and administrative expenses also include facility expenses, professional fees for legal, consulting, accounting and audit services and other related costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses may increase as the Company focuses on the continued development of the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> OPMD program. The Company also anticipates an increase in expenses relating to accounting, legal and regulatory-related services associated with maintaining compliance with the exchange listing and the
SEC requirements, director and officer insurance premiums and other costs associated with being a domestic public company after the <FONT STYLE="white-space:nowrap">Re-domiciliation</FONT> and no longer a &#147;foreign private issuer&#148; under SEC
rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following tables set forth a summary of our expenses for each of the periods set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three&nbsp;Months&nbsp;Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalties and license fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2020, we incurred $134 in royalties and license fees, as
compared to $26 for the comparable year ended September&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2020, we incurred
$774 in research and development expenses, as compared $423 for the comparable three months ended September&nbsp;30, 2019. The increase in research and development expenses is primarily due to the impact in three months ended September&nbsp;30, 2019
of the Company being reimbursed $618<B></B>&nbsp;by Axovant Sciences for costs relating to the OPMD program and the termination of the AMD program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense was $1,837 and $750 for the three months ended September&nbsp;30, 2020 and 2019, respectively. The increase
was due to increases in corporate costs and office costs offset by decreases in employee related costs, depreciation, consulting costs, travel related costs and share based payment costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Loss) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
tables set forth a summary of our other income (loss) for each of the periods set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three&nbsp;Months&nbsp;Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Income (Loss):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency transaction loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (loss), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on investment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (loss), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The other loss, net during the three months ended September&nbsp;30, 2020 totaled ($28),
which consists of foreign currency transaction loss, interest loss, and other income. During the three months ended September&nbsp;30, 2019, other income, net totaled $19. Foreign currency transaction loss has increased due to a change in foreign
exchange rates. Interest income decreased due to fewer transactions with interest. Other income, net increased due <FONT STYLE="white-space:nowrap">to&nbsp;COVID-19&nbsp;stimulus</FONT> incentives from the Australian government. Unrealized gain on
investment increased due to the change in fair market value of the investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our net income (loss) for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three&nbsp;Months&nbsp;Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">September&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,718</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,147</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the changes in revenues and expenses noted above, our net income (loss) increased from
approximately $(1,147) in the three months ended September&nbsp;30, 2019 to $(2,718) in the three months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and
Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred cumulative losses and negative cash flows from operations since our predecessor&#146;s
inception in 1995. The Company had accumulated losses of $119.3&nbsp;million as of September&nbsp;30, 2020. We expect that our research and development expenses may increase due to the continued development of the OPMD program. It is also likely
that there will be an increase in the general and administrative expenses due to the obligations of being a domestic public company in the United States as a result of <FONT STYLE="white-space:nowrap">the&nbsp;Re-domiciliation&nbsp;and</FONT> no
longer a &#147;foreign private issuer&#148; under SEC Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had no borrowings for the three months ended September&nbsp;30, 2020 and
2019 and do not currently have a credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2020, we had cash and cash equivalents of $7.5&nbsp;million.
Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our cash and cash equivalents are held in bank accounts. Our short-term
investments consist of term deposits with maturity within 180 days. Based on cash and cash equivalents of the Company, including proceeds from a public offering of common stock (and common stock equivalents) that closed on October&nbsp;6, 2020
management estimates that cash and cash equivalents will be sufficient to fund the Company&#146;s operations for at least the next twelve months from the filing of this form&nbsp;10-Q. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods set forth below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three&nbsp;Months&nbsp;Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(US$&#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(173</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the three months ended September&nbsp;30, 2020 and 2019 was $2,360 and $545, respectively. Net cash
used in operating activities was primarily the result of our net loss and change in working capital, partially offset by equity-based compensation expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in
investing activities for the three months ended September&nbsp;30, 2020 was $173. Net cash provided by investing activities for the three months ended September&nbsp;30, 2019 was $1. The change was primarily related to purchases of equipment in 2020
compared to proceeds from disposal of property and equipment in the same period 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $0 and $1,770 for the three months ended September&nbsp;30, 2020 and 2019, respectively. Cash
from financing activities related to the issuance of ordinary shares, including $2,250 in gross proceeds from a private placement and entitlement offer, partially offset by $480 in share issue transaction costs in the prior period. There were no
private placements or public offering completed during the three months ended September&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to September&nbsp;30,
2020, we completed on October&nbsp;6, 2020 an underwritten public offering of 3,225,806 shares of our common stock (or common stock equivalents in lieu thereof) at a price to the public of $3.10 per share. The underwriter also fully exercised its
over-allotment option to purchase 483,870 additional shares of its common stock. The Company received gross proceeds of approximately $11.5&nbsp;million and net proceeds of approximately $9.9&nbsp;million from the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The future of the Company as an operating business will depend on its ability to generate revenues mostly from licensing, strategic alliances
and collaboration arrangements with pharmaceutical companies. While we continue to progress discussions and advance opportunities to engage with pharmaceutical companies and continue to seek licensing partners for ddRNAi in disease areas that are
not our focus, there can be no assurance as to whether we will enter into such arrangements or what the terms of any such arrangement could be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have established some licensing arrangements, we do not have any products approved for sale and have not generated any revenue from
product sales. We do not know when, or if, we will generate any revenue from product sales. We do not expect to generate significant revenue from product sales unless and until we obtain regulatory approval of and commercialize one of our current or
future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until we establish significant revenues from licensing programs, strategic alliances or
collaboration arrangements with pharmaceutical companies, or from product sales, we anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of product
candidates and begin to prepare to commercialize any product that receives regulatory approval. We are subject to the risks inherent in the development of new gene therapy products, and we may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. We estimate that our cash and cash equivalents will be sufficient to fund the Company&#146;s operations at least for the next twelve months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our projections of operating capital requirements on assumptions that may
prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable
to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the timing and costs of our planned clinical trials for our ddRNAi and silence and replace product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the timing and costs of our planned preclinical studies for our ddRNAi and silence and replace product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number and characteristics of product candidates that we pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the outcome, timing and costs of seeking regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">revenue received from commercial sales of any of our product candidates that may receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may
establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount and timing of any payments we may be required to make, or that we may receive, in connection with
the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual
property rights and defending against intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the extent to which we need <FONT STYLE="white-space:nowrap">to&nbsp;in-license&nbsp;or</FONT> acquire other
products and technologies. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commercial Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;9, 2018, the Company entered into an Agreement with Axovant Sciences. The Agreement granted Axovant Sciences an exclusive
worldwide license to develop, manufacture, and commercialize products containing the Company&#146;s product known <FONT STYLE="white-space:nowrap">as&nbsp;BB-301,&nbsp;which</FONT> was designed for the potential treatment of Oculopharyngeal Muscular
Dystrophy. On June&nbsp;6, 2019, the termination of the Agreement with Axovant Sciences was announced. The termination of the Agreement was effective as of September&nbsp;3, 2019. The termination discharges all future performance obligations at
termination date under the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had no <FONT STYLE="white-space:nowrap">material&nbsp;off-balance&nbsp;sheet</FONT> arrangements as of September&nbsp;30, 2020.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the
United States of America requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of the Notes to Consolidated Financial Statements included in this Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> describes the significant accounting policies used in the preparation of the consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting
policies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A critical accounting policy is defined as one that is both material to the presentation of the Company&#146;s consolidated
financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on the Company&#146;s financial condition or results of operations. Specifically, these policies have the following
attributes: (1)&nbsp;the Company is required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2)&nbsp;different estimates the Company could reasonably have used, or changes in the estimate that are
reasonably likely to occur, would have a material effect on the Company&#146;s financial condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimates and assumptions about future events and their effects cannot be determined with
certainty. The Company bases its estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is
obtained and as the Company&#146;s operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, management is periodically faced
with uncertainties, the outcomes of which are not within its control and will not be known for prolonged periods of time. These uncertainties are discussed in the section above entitled &#147;Risk Factors.&#148; Based on a critical assessment of its
accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that the Company&#146;s consolidated financial statements are fairly stated in accordance with accounting principles
generally accepted in the United States of America, and provide a meaningful presentation of the Company&#146;s financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that the following are critical accounting policies: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
adopted and implemented on July&nbsp;1, 2018, ASC 606&#151;&#147;<I>Revenue from Contracts with Customers</I>&#148; (&#147;ASC 606&#148;). ASC 606 did not have a material impact on the consolidated financial statements. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon implementation of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 1: Identify the contract(s) with a customer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 2: Identify the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 3: Determine the transaction price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 4: Allocate the transaction price to the performance obligations in the contract. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC&nbsp;606. In doing so, management
considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the
contract was within the scope of ASC 606. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has also made the judgement that the grant of the license and transfer of <FONT
STYLE="white-space:nowrap">associated&nbsp;know-how&nbsp;and</FONT> materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer
independently from each other. Judgements were made in relation to the transfer of the license <FONT STYLE="white-space:nowrap">and&nbsp;know-how&nbsp;and</FONT> whether this should be recognized over time or a point in time. The point in time has
been determined with regard to the point at which the transfer <FONT STYLE="white-space:nowrap">of&nbsp;know-how&nbsp;has</FONT> substantially been completed and the customer has control of the asset and the ability to direct the use of and receive
substantially all of the remaining benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licensing revenues </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflects the transfer of a right to use the intellectual property as it
exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a
significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these
amounts as other liabilities in the statement of financial position. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its statement
of financial position, depending on whether something other than the passage of time is required before the consideration is due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from licensees of the Company&#146;s intellectual property reflect a right to use the intellectual property as it exists at the point
in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#146;s subsequent sales of product occurs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Services revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is earned
(constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision
of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company records share-based compensation in accordance with ASC 718, &#147;<I>Stock Compensation</I>&#148;. ASC&nbsp;718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the
shorter of the service period or the vesting period. The Company values employee <FONT STYLE="white-space:nowrap">and&nbsp;non-employee&nbsp;share-based</FONT> compensation at fair value using the Black-Scholes Option Pricing Model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company adopted <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07&nbsp;and</FONT> accounts
<FONT STYLE="white-space:nowrap">for&nbsp;non-employee&nbsp;share-based</FONT> awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. There was no
cumulative effect of adoption on July&nbsp;1, 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounting Standards recently adopted </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>New Accounting Standards and Interpretations not yet mandatory or early adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>ASU</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;2016-13</FONT></B>&#151;In June 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-13:&nbsp;&#147;</FONT><I>Financial Instruments&#151;Credit Losses</I>&nbsp;(Topic 326)&#148;. This ASU represents a significant change in the accounting for credit losses model by requiring
immediate recognition of management&#146;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet
have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&nbsp;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company
(&#147;SRC&#148;) as of November&nbsp;15, 2019. As such, <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-10:&nbsp;&#147;</FONT><I>Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&#148;</I><I></I>&nbsp;amended
the effective date for the Company to be for reporting periods beginning after December&nbsp;15, 2022. The Company will adopt this ASU effective July&nbsp;1, 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_10"></A>Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a smaller reporting company, we are not required to provide the information pursuant to this Item. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_11"></A>Item&nbsp;4. Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established disclosure controls and procedures (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e)</FONT> under the Securities Exchange Act of 1934, as amended). As of the end of the period covered by this report we carried out an evaluation under the supervision and with the participation of our management,
including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13a-15</FONT> of the
Securities and Exchange Act of 1934, as amended. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes in our internal controls over financial reporting during the quarter ended September&nbsp;30, 2020 that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect that our
disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_12"></A>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>OTHER INFORMATION </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_13">
</A>Item&nbsp;1. Legal Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a party to any material legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_14"></A>Item&nbsp;1A. Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There have been no material changes to the risk factors disclosed in Item 1A of the Company&#146;s Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the period ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_15"></A>Item&nbsp;2. Unregistered Sales
of Equity Securities and Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_16"></A>Item&nbsp;3. Defaults Upon Senior Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_17"></A>Item&nbsp;4. Mine Safety Disclosures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_18"></A>Item&nbsp;5. Other Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin943701_19"></A>Item&nbsp;6. Exhibits. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center">Number</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Description of Document</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d943701dex311.htm">Statement of CEO Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d943701dex312.htm">Statement of CFO Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002*</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d943701dex321.htm">Statement of CEO Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002**</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>32.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d943701dex322.htm">Statement of CFO Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002**</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Calculation Linkbase Document*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Label Linkbase Document*</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document*</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Furnished, not filed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin943701_20"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Benitec Biopharma Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: November 13, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Megan Boston<B><I> </I></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Director (principal accounting and financial officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and Chief Executive Officer (principal executive officer)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d943701dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 31.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Jerel Banks,<B> </B>certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 13, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d943701dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 31.2 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Megan Boston,<B> </B>certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma
Inc.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this<B> </B>report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November 13, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Megan Boston</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Executive Director (principal
financial officer)</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d943701dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 32.1 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Executive
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: November 13, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">I,
Jerel Banks, Chief Executive Officer of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1. the accompanying Quarterly
Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma Inc. for the three month period ended September&nbsp;30, 2020 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or 15(d), as
applicable, of the Securities and Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of Benitec Biopharma Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned
has executed this Statement as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jerel Banks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jerel Banks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d943701dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>EXHIBIT 32.2 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statement Pursuant to Section&nbsp;906 the Sarbanes-Oxley Act of 2002 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>By </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Principal Financial
Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Regarding Facts and Circumstances Relating to Exchange Act Filings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Dated: November 13, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">I,
Megan Boston, Executive Director (principal accounting officer) of Benitec Biopharma Inc., hereby certify, to my knowledge, that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1. the
accompanying Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of Benitec Biopharma Inc. for the three month period ended September&nbsp;30, 2020 (the &#147;Report&#148;) fully complies with the requirements of Section&nbsp;13(a)
or 15(d), as applicable, of the Securities and Exchange Act of 1934, as amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of Benitec Biopharma Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Megan Boston</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Megan Boston</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Executive Director (principal accounting officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>bntc-20200930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<xbrli:xbrl xmlns:bntc="http://www.benitecbiopharmainc.com/20200930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31">
<link:schemaRef xlink:type="simple" xlink:href="bntc-20200930.xsd" />
<xbrli:context id="PAsOn09_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P11_27_2019To11_27_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-11-27</xbrli:startDate>
<xbrli:endDate>2019-11-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn11_09_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-11-09</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_06_2020To10_06_2020">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-06</xbrli:startDate>
<xbrli:endDate>2020-10-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedBblMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecBiopharmaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_RoyaltyMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_ServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bntc:LabEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bntc:GrantReceivableOnResearchAndDevelopmentExpendituresMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-07-01</xbrli:startDate>
<xbrli:endDate>2020-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_RoyaltyMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_ServiceMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_ServiceMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_LicenseMembersrtProductOrServiceAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To09_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecAustraliaProprietaryLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:BenitecLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:RnaiTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bntc:TacereTherapeuticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2020-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-10-06</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-10-06</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-06</xbrli:startDate>
<xbrli:endDate>2020-10-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-06</xbrli:startDate>
<xbrli:endDate>2020-10-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bntc:PreFundedWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-10-06</xbrli:startDate>
<xbrli:endDate>2020-10-06</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="PAsOn09_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001808898</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-09-30</xbrli:instant>
</xbrli:period>
</xbrli:context>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_15653935" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">7450000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_15653936" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">9801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsAndOtherReceivablesNetCurrent id="Factid_15653937" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">18000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:AccountsAndOtherReceivablesNetCurrent id="Factid_15653938" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">59000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_15653939" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">588000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent id="Factid_15653940" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">949000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_15653941" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">8056000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent id="Factid_15653942" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">10809000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_15653943" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">503000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet id="Factid_15653944" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">374000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:DepositAssets id="Factid_15653945" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:DepositAssets>
<us-gaap:DepositAssets id="Factid_15653946" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">9000</us-gaap:DepositAssets>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_15653947" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">348000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:Assets id="Factid_15653948" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">8916000</us-gaap:Assets>
<us-gaap:Assets id="Factid_15653949" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">11587000</us-gaap:Assets>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent id="Factid_15653950" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">624000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent id="Factid_15653951" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">741000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_15653952" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">197000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:EmployeeRelatedLiabilitiesCurrent id="Factid_15653953" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">203000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent id="Factid_15653954" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">198000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_15653955" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">1019000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent id="Factid_15653956" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1136000</us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent id="Factid_15653957" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">161000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities id="Factid_15653958" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">1180000</us-gaap:Liabilities>
<us-gaap:Liabilities id="Factid_15653959" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1349000</us-gaap:Liabilities>
<us-gaap:CommonStockValue id="Factid_15653962" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">1000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue id="Factid_15653963" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_15653964" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">128850000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock id="Factid_15653965" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">128826000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_15653966" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">-119340000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit id="Factid_15653967" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">-116636000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Factid_15653968" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">-1775000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="Factid_15653969" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">-1953000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity id="Factid_15653970" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">7736000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15653971" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">10238000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_15653972" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">8916000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity id="Factid_15653973" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">11587000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:NetIncomeLoss id="Factid_15653974" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2718000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss id="Factid_15653975" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1147000</us-gaap:NetIncomeLoss>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_15653976" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">45000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization id="Factid_15653977" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">51000</us-gaap:DepreciationDepletionAndAmortization>
<bntc:AmortizationOfRightOfUseAssets id="Factid_15653978" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">47000</bntc:AmortizationOfRightOfUseAssets>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Factid_15653980" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:ShareBasedCompensation id="Factid_15653981" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">38000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation id="Factid_15653982" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">55000</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="Factid_15653983" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-27000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables id="Factid_15653984" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-974000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="Factid_15653985" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-374000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<us-gaap:IncreaseDecreaseInOtherOperatingAssets id="Factid_15653986" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-130000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
<bntc:IncreasedecreaseInAccountsAndOtherPayables id="Factid_15653987" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-119000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
<bntc:IncreasedecreaseInAccountsAndOtherPayables id="Factid_15653988" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-645000</bntc:IncreasedecreaseInAccountsAndOtherPayables>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Factid_15653989" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-8000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="Factid_15653990" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">18000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
<bntc:IncreaseDecreaseInLeaseLiabilities id="Factid_15653991" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-46000</bntc:IncreaseDecreaseInLeaseLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_15653992" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2360000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities id="Factid_15653993" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-545000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Factid_15653994" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">173000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15653997" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15653998" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">33000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:Revenues id="Factid_15653999" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">55000</us-gaap:Revenues>
<us-gaap:Revenues id="Factid_15654000" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">33000</us-gaap:Revenues>
<bntc:RoyaltiesAndLicenseFees id="Factid_15654001" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">134000</bntc:RoyaltiesAndLicenseFees>
<bntc:RoyaltiesAndLicenseFees id="Factid_15654002" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">26000</bntc:RoyaltiesAndLicenseFees>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_15654003" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">774000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense id="Factid_15654004" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">423000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_15654005" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">1837000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense id="Factid_15654006" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">750000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses id="Factid_15654007" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">2745000</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses id="Factid_15654008" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1199000</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss id="Factid_15654009" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2690000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss id="Factid_15654010" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1166000</us-gaap:OperatingIncomeLoss>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Factid_15654011" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="Factid_15654012" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InterestIncomeExpenseNonoperatingNet id="Factid_15654013" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-1000</us-gaap:InterestIncomeExpenseNonoperatingNet>
<us-gaap:InterestIncomeExpenseNonoperatingNet id="Factid_15654014" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">18000</us-gaap:InterestIncomeExpenseNonoperatingNet>
<us-gaap:OtherNonoperatingIncomeExpense id="Factid_15654015" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">27000</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_15654016" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">0</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_15654017" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:UnrealizedGainLossOnInvestments>
<us-gaap:NonoperatingIncomeExpense id="Factid_15654018" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-28000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense id="Factid_15654019" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">19000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_15654022" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_15654023" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-304000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="Factid_15654024" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">178000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent id="Factid_15654025" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-304000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_15654026" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2540000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax id="Factid_15654027" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-1451000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_15654028" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2">-2.45</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted id="Factid_15654029" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD_per_Share" decimals="2">-1.34</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_15654030" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="0">1108374</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Factid_15654031" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="0">858794</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_15654032" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">55000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_15654033" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">55000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_15654034" contextRef="P07_01_2019To09_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-304000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:SharesOutstanding id="Factid_15654036" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_15654037" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654039" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-116636000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654040" contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1953000</us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_15654042" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">38000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="Factid_15654043" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">38000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax id="Factid_15654044" contextRef="P07_01_2020To09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">178000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Factid_15654046" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_15654047" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-173000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities id="Factid_15654048" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_15654052" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">-2533000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="Factid_15654053" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1226000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_15654056" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">182000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Factid_15654057" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-313000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_15654059" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">16631000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues id="Factid_15654067" contextRef="P07_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">186666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_15654068" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1720000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues id="Factid_15654069" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1720000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_15654070" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-61000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_15654071" contextRef="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">61000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:NetIncomeLoss id="Factid_15654072" contextRef="P07_01_2019To09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1147000</us-gaap:NetIncomeLoss>
<us-gaap:SharesOutstanding id="Factid_15654074" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1043431</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_15654075" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654076" contextRef="PAsOn09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">129091000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654077" contextRef="PAsOn09_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-109956000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654078" contextRef="PAsOn09_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-2168000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654079" contextRef="PAsOn09_30_2019" unitRef="Unit_USD" decimals="-3">16968000</us-gaap:StockholdersEquity>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_15654080" contextRef="P07_01_2020To09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited id="Factid_15654081" contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:SharesOutstanding id="Factid_15654082" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:SharesOutstanding>
<us-gaap:StockholdersEquity id="Factid_15654083" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654084" contextRef="PAsOn09_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">128850000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654085" contextRef="PAsOn09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-119340000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15654086" contextRef="PAsOn09_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1775000</us-gaap:StockholdersEquity>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654089" contextRef="PAsOn06_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654090" contextRef="PAsOn06_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654091" contextRef="PAsOn06_30_2019_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654092" contextRef="PAsOn06_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654093" contextRef="PAsOn06_30_2019_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654094" contextRef="PAsOn06_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654095" contextRef="PAsOn06_30_2019_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654096" contextRef="PAsOn06_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654097" contextRef="PAsOn06_30_2019_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654098" contextRef="PAsOn06_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654099" contextRef="PAsOn06_30_2019_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654100" contextRef="PAsOn06_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage id="Factid_15654101" contextRef="PAsOn06_30_2019_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" unitRef="Unit_pure" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_15654102" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="INF">145421</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Factid_15654103" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_shares" decimals="INF">65852</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ConcentrationRiskPercentage1 id="Factid_15654104" contextRef="P07_01_2020To09_30_2020_GrantReceivableOnResearchAndDevelopmentExpendituresMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="3">0.435</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654110" contextRef="P07_01_2019To09_30_2019_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654111" contextRef="P07_01_2020To09_30_2020_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654113" contextRef="P07_01_2020To09_30_2020_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654120" contextRef="P07_01_2020To09_30_2020_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654125" contextRef="P07_01_2019To09_30_2019_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654127" contextRef="P07_01_2019To09_30_2019_RoyaltyMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654129" contextRef="P07_01_2019To09_30_2019_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654131" contextRef="P07_01_2019To09_30_2019_RoyaltyMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">29000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654132" contextRef="P07_01_2019To09_30_2019_ServiceMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:DueFromBanks id="Factid_15654134" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">7450000</us-gaap:DueFromBanks>
<us-gaap:DueFromBanks id="Factid_15654135" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">5231000</us-gaap:DueFromBanks>
<us-gaap:TimeDepositsAtCarryingValue id="Factid_15654136" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">0</us-gaap:TimeDepositsAtCarryingValue>
<us-gaap:TimeDepositsAtCarryingValue id="Factid_15654137" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">4570000</us-gaap:TimeDepositsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent id="Factid_15654144" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">564000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent id="Factid_15654145" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">861000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:SecurityDeposit id="Factid_15654146" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">14000</us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit id="Factid_15654147" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">69000</us-gaap:SecurityDeposit>
<bntc:Otherdeposits id="Factid_15654148" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">9000</bntc:Otherdeposits>
<bntc:Otherdeposits id="Factid_15654149" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">18000</bntc:Otherdeposits>
<bntc:MarketValueOfListedShares id="Factid_15654150" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">1000</bntc:MarketValueOfListedShares>
<bntc:MarketValueOfListedShares id="Factid_15654151" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1000</bntc:MarketValueOfListedShares>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654154" contextRef="PAsOn09_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654155" contextRef="PAsOn06_30_2020_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">11000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654156" contextRef="PAsOn09_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">1283000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654157" contextRef="PAsOn06_30_2020_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">1109000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654159" contextRef="PAsOn09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">26000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654160" contextRef="PAsOn06_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">26000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654161" contextRef="PAsOn09_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">24000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654162" contextRef="PAsOn06_30_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3">24000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654163" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">1344000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross id="Factid_15654164" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">1170000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_15654165" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">841000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="Factid_15654166" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">796000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:Depreciation id="Factid_15654169" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="0">45000</us-gaap:Depreciation>
<us-gaap:Depreciation id="Factid_15654170" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="0">51000</us-gaap:Depreciation>
<us-gaap:AccountsPayableTradeCurrent id="Factid_15654171" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">299000</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableTradeCurrent id="Factid_15654172" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">282000</us-gaap:AccountsPayableTradeCurrent>
<bntc:AccruedLicenceFeesCurrent id="Factid_15654173" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">171000</bntc:AccruedLicenceFeesCurrent>
<bntc:AccruedLicenceFeesCurrent id="Factid_15654174" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">54000</bntc:AccruedLicenceFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_15654175" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">43000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent id="Factid_15654176" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">155000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_15654177" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">111000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent id="Factid_15654178" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">250000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:LesseeOperatingLeaseRemainingLeaseTerm id="Factid_15654181" contextRef="PAsOn09_30_2020">P1Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
<us-gaap:LesseeOperatingLeaseDiscountRate id="Factid_15654182" contextRef="PAsOn09_30_2020" unitRef="Unit_pure" decimals="4">0.0467</us-gaap:LesseeOperatingLeaseDiscountRate>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="Factid_15654183" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">156000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo id="Factid_15654184" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">218000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="Factid_15654185" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">375000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount id="Factid_15654186" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">16000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:OperatingLeaseLiability id="Factid_15654187" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="-3">359000</us-gaap:OperatingLeaseLiability>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654188" contextRef="P07_01_2020To09_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">9000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_15654189" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="0">145421</us-gaap:ClassOfWarrantOrRightOutstanding>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding id="Factid_15654190" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="2">29.48</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_15654193" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">70161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_15654194" contextRef="PAsOn06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">60.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Factid_15654198" contextRef="P07_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Factid_15654199" contextRef="P07_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">69.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Factid_15654200" contextRef="PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">69717</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Factid_15654201" contextRef="PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">60.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Factid_15654203" contextRef="PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0">43273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Factid_15654204" contextRef="PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2">68.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654205" contextRef="P07_01_2019To09_30_2019_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">-17000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654206" contextRef="P07_01_2020To09_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">29000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654207" contextRef="P07_01_2019To09_30_2019_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3">72000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654208" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">38000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense id="Factid_15654209" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">55000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Factid_15654210" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" decimals="0">119000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:RevenueFromContractWithCustomerTextBlock id="Factid_15654299" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Revenue &lt;/div&gt;(US$&amp;#8217;000) &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:73%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;Revenues from customers&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Licensing revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Service revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;* On July&amp;#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&amp;#8217;s product &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301,&lt;/div&gt; which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company&amp;#8217;s intellectual property related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; and the transfer of the right to use the intellectual property of the Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&amp;#160;6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September&amp;#160;3, 2019. The termination discharges all future performance obligations at termination date under the contract.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:60%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Licensing&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Royalties&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Development&amp;#160;activities&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:63%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Licensing&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Royalties&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Development&amp;#160;activities&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
<us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock id="Factid_15654300" contextRef="P07_01_2020To09_30_2020">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:73%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:11%;"&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:bottom;"&gt;Revenues from customers&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Licensing revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Service revenue*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;* On July&amp;#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&amp;#8217;s product &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301,&lt;/div&gt; which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company&amp;#8217;s intellectual property related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; and the transfer of the right to use the intellectual property of the Company&amp;#8217;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BB-301&lt;/div&gt; license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&amp;#160;6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September&amp;#160;3, 2019. The termination discharges all future performance obligations at termination date under the contract.&lt;/div&gt;&lt;div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
<us-gaap:DisaggregationOfRevenueTableTextBlock id="Factid_15654314" contextRef="P07_01_2020To09_30_2020">&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:60%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Licensing&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Royalties&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Development&amp;#160;activities&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:63%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Disaggregated revenue&amp;#160;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended September&amp;#160;30, 2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Licensing&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Royalties&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Development&amp;#160;activities&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Services transferred at a point in time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Services transferred over time&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;4&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;33&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654346" contextRef="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis_TransferredOverTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654347" contextRef="P07_01_2020To09_30_2020_LicenseMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3">55000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax id="Factid_15654348" contextRef="P07_01_2019To09_30_2019_ServiceMembersrtProductOrServiceAxis_TransferredAtPointInTimeMemberusgaapTimingOfTransferOfGoodOrServiceAxis" unitRef="Unit_USD" decimals="-3">4000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
<dei:DocumentType id="Factid_15654425" contextRef="P07_01_2020To09_30_2020">10-Q</dei:DocumentType>
<dei:AmendmentFlag id="Factid_15654426" contextRef="P07_01_2020To09_30_2020">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate id="Factid_15654430" contextRef="P07_01_2020To09_30_2020">2020-09-30</dei:DocumentPeriodEndDate>
<us-gaap:ClassOfWarrantOrRightOutstanding id="Factid_15654438" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="0">107095</us-gaap:ClassOfWarrantOrRightOutstanding>
<dei:DocumentFiscalYearFocus id="Factid_15654439" contextRef="P07_01_2020To09_30_2020">2021</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus id="Factid_15654440" contextRef="P07_01_2020To09_30_2020">Q1</dei:DocumentFiscalPeriodFocus>
<dei:EntityRegistrantName id="Factid_15654441" contextRef="P07_01_2020To09_30_2020">Benitec Biopharma Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey id="Factid_15654446" contextRef="P07_01_2020To09_30_2020">0001808898</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate id="Factid_15654447" contextRef="P07_01_2020To09_30_2020">--06-30</dei:CurrentFiscalYearEndDate>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding id="Factid_15654448" contextRef="PAsOn09_30_2020" unitRef="Unit_USD_per_Share" decimals="2">10.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding>
<dei:EntityCurrentReportingStatus id="Factid_15654464" contextRef="P07_01_2020To09_30_2020">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent id="Factid_15654465" contextRef="P07_01_2020To09_30_2020">Yes</dei:EntityInteractiveDataCurrent>
<dei:DocumentQuarterlyReport id="Factid_15654471" contextRef="P07_01_2020To09_30_2020">true</dei:DocumentQuarterlyReport>
<dei:DocumentTransitionReport id="Factid_15654472" contextRef="P07_01_2020To09_30_2020">false</dei:DocumentTransitionReport>
<dei:EntityIncorporationStateCountryCode id="Factid_15654476" contextRef="P07_01_2020To09_30_2020">DE</dei:EntityIncorporationStateCountryCode>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Factid_15654486" contextRef="P07_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<dei:EntityAddressAddressLine1 id="Factid_15654487" contextRef="P07_01_2020To09_30_2020">3940 Trust Way Hayward</dei:EntityAddressAddressLine1>
<dei:EntityAddressCountry id="Factid_15654488" contextRef="P07_01_2020To09_30_2020">CA</dei:EntityAddressCountry>
<dei:EntityAddressPostalZipCode id="Factid_15654489" contextRef="P07_01_2020To09_30_2020">94545</dei:EntityAddressPostalZipCode>
<dei:CityAreaCode id="Factid_15654494" contextRef="P07_01_2020To09_30_2020">(510)</dei:CityAreaCode>
<dei:LocalPhoneNumber id="Factid_15654495" contextRef="P07_01_2020To09_30_2020">780-0819</dei:LocalPhoneNumber>
<dei:Security12bTitle id="Factid_15654496" contextRef="P07_01_2020To09_30_2020">Common stock</dei:Security12bTitle>
<dei:TradingSymbol id="Factid_15654497" contextRef="P07_01_2020To09_30_2020">BNTC</dei:TradingSymbol>
<dei:SecurityExchangeName id="Factid_15654498" contextRef="P07_01_2020To09_30_2020">NASDAQ</dei:SecurityExchangeName>
<dei:EntityFilerCategory id="Factid_15654505" contextRef="P07_01_2020To09_30_2020">Non-accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness id="Factid_15654507" contextRef="P07_01_2020To09_30_2020">true</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany id="Factid_15654508" contextRef="P07_01_2020To09_30_2020">true</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany id="Factid_15654510" contextRef="P07_01_2020To09_30_2020">false</dei:EntityShellCompany>
<dei:EntityCommonStockSharesOutstanding id="Factid_15654512" contextRef="PAsOn11_09_2020" unitRef="Unit_shares" decimals="INF">4405469</dei:EntityCommonStockSharesOutstanding>
<dei:EntityFileNumber id="Factid_15654518" contextRef="P07_01_2020To09_30_2020">001-39267</dei:EntityFileNumber>
<us-gaap:OperatingLeaseRightOfUseAsset id="Factid_15654552" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">395000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseLiabilityCurrent id="Factid_15654553" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">192000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent id="Factid_15654554" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3">213000</us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives id="Factid_15654574" contextRef="P07_01_2020To09_30_2020_LeaseholdsAndLeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">shorter of the lease term or estimated useful lives</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654579" contextRef="P07_01_2020To09_30_2020_MinimumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654580" contextRef="P07_01_2020To09_30_2020_MaximumMembersrtRangeAxis_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654581" contextRef="P07_01_2020To09_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654582" contextRef="P07_01_2020To09_30_2020_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654583" contextRef="P07_01_2020To09_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654584" contextRef="P07_01_2020To09_30_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654585" contextRef="P07_01_2020To09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife id="Factid_15654586" contextRef="P07_01_2020To09_30_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<bntc:FinancialAssetsAtFairValue id="Factid_15654588" contextRef="PAsOn09_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</bntc:FinancialAssetsAtFairValue>
<bntc:FinancialAssetsAtFairValue id="Factid_15654591" contextRef="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</bntc:FinancialAssetsAtFairValue>
<us-gaap:FinancialLiabilitiesFairValueDisclosure id="Factid_15654593" contextRef="PAsOn09_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure id="Factid_15654594" contextRef="PAsOn06_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="INF">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_15654595" contextRef="PAsOn09_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_15654596" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued id="Factid_15654597" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Factid_15654598" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare id="Factid_15654600" contextRef="PAsOn06_30_2020" unitRef="Unit_USD_per_Share" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized id="Factid_15654601" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">10000000</us-gaap:CommonStockSharesAuthorized>
<dei:EntityIncorporationStateCountryCode id="Factid_15654944" contextRef="P07_01_2020To09_30_2020_BenitecBiopharmaProprietaryLimitedBblMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654945" contextRef="P07_01_2020To09_30_2020_BenitecAustraliaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654946" contextRef="P07_01_2020To09_30_2020_BenitecBiopharmaProprietaryLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">C3</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654947" contextRef="P07_01_2020To09_30_2020_BenitecLimitedMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X0</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654948" contextRef="P07_01_2020To09_30_2020_BenitecIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654949" contextRef="P07_01_2020To09_30_2020_BenitecLlcMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654950" contextRef="P07_01_2020To09_30_2020_RnaiTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationStateCountryCode id="Factid_15654951" contextRef="P07_01_2020To09_30_2020_TacereTherapeuticsIncMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">X1</dei:EntityIncorporationStateCountryCode>
<dei:EntityIncorporationDateOfIncorporation id="Factid_15654966" contextRef="P07_01_2020To09_30_2020">2019-11-22</dei:EntityIncorporationDateOfIncorporation>
<bntc:CommonStockSharesRedomiciliationDescription id="Factid_15654968" contextRef="P11_27_2019To11_27_2019">one Benitec Biopharma Inc. share for every 300 BBL shares</bntc:CommonStockSharesRedomiciliationDescription>
<bntc:AmortizationOfRightOfUseAssets id="Factid_15654976" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">46000</bntc:AmortizationOfRightOfUseAssets>
<us-gaap:UnrealizedGainLossOnInvestments id="Factid_15654982" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1000</us-gaap:UnrealizedGainLossOnInvestments>
<bntc:IncreaseDecreaseInLeaseLiabilities id="Factid_15654990" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">-27000</bntc:IncreaseDecreaseInLeaseLiabilities>
<us-gaap:ProceedsFromIssuanceOfCommonStock id="Factid_15654996" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">2250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_15654997" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">480000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities id="Factid_15654998" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">1770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability id="Factid_15655002" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">579000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
<us-gaap:StockholdersEquity id="Factid_15655023" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">128826000</us-gaap:StockholdersEquity>
<us-gaap:SharesOutstanding id="Factid_15655033" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF">856765</us-gaap:SharesOutstanding>
<bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts id="Factid_15655044" contextRef="P07_01_2019To09_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">50000</bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts>
<bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts id="Factid_15655045" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">50000</bntc:IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts>
<us-gaap:NetIncomeLoss id="Factid_15655060" contextRef="P07_01_2020To09_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-2718000</us-gaap:NetIncomeLoss>
<bntc:ClassOfWarrantsOrRightsGrantsInPeriod id="Factid_15655740" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="0">0</bntc:ClassOfWarrantsOrRightsGrantsInPeriod>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod id="Factid_15655741" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="0">0</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod>
<bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod id="Factid_15655742" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="0">0</bntc:ClassOfWarrantsOrRightsExcercisedDuringThePeriod>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod id="Factid_15655743" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="0">0</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod>
<bntc:ClassOfWarrantsOrRightsCashlessExerciseOfWarrants id="Factid_15655744" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_shares" decimals="0">38326</bntc:ClassOfWarrantsOrRightsCashlessExerciseOfWarrants>
<bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants id="Factid_15655745" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD_per_Share" decimals="2">82.50</bntc:WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants>
<us-gaap:OperatingLeasesRentExpenseNet id="Factid_15665881" contextRef="P07_01_2020To09_30_2020" unitRef="Unit_USD" decimals="-3">52000000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet id="Factid_15665883" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">52000000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:StockholdersEquity id="Factid_15665958" contextRef="PAsOn06_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">1000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15665959" contextRef="PAsOn06_30_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">127327000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15665962" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">16594000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15665969" contextRef="PAsOn06_30_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-108870000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity id="Factid_15665972" contextRef="PAsOn06_30_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3">-1864000</us-gaap:StockholdersEquity>
<us-gaap:CashAndCashEquivalentsAtCarryingValue id="Factid_15666027" contextRef="PAsOn06_30_2019" unitRef="Unit_USD" decimals="-3">15718000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<dei:EntityExTransitionPeriod id="Factid_15666099" contextRef="P07_01_2020To09_30_2020">true</dei:EntityExTransitionPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_15666429" contextRef="P07_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Factid_15666430" contextRef="P07_01_2019To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P2Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Factid_15673516" contextRef="P10_06_2020To10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">3225806</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare id="Factid_15673517" contextRef="PAsOn10_06_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2">3.10</us-gaap:SaleOfStockPricePerShare>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Factid_15673518" contextRef="P10_06_2020To10_06_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">483870</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Factid_15673519" contextRef="P10_06_2020To10_06_2020" unitRef="Unit_shares" decimals="0">3709676</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<bntc:CommonStockEquivalents id="Factid_15673520" contextRef="P10_06_2020To10_06_2020" unitRef="Unit_shares" decimals="0">2666644</bntc:CommonStockEquivalents>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Factid_15673521" contextRef="P10_06_2020To10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0">559162</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockPricePerShare id="Factid_15673522" contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2">3.09</us-gaap:SaleOfStockPricePerShare>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Factid_15673523" contextRef="PAsOn10_06_2020_PreFundedWarrantsMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<bntc:GrossProceedsFromIssueOfStock id="Factid_15673524" contextRef="P10_06_2020To10_06_2020" unitRef="Unit_USD" decimals="-5">11500000</bntc:GrossProceedsFromIssueOfStock>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering id="Factid_15673525" contextRef="P10_06_2020To10_06_2020" unitRef="Unit_USD" decimals="-5">9900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:CommitmentsAndContingencies id="Factid_15686780" contextRef="PAsOn09_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommitmentsAndContingencies id="Factid_15686781" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" xsi:nil="true" />
<us-gaap:CommonStockSharesIssued id="Factid_15686783" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding id="Factid_15686784" contextRef="PAsOn06_30_2020" unitRef="Unit_shares" decimals="INF">1108374</us-gaap:CommonStockSharesOutstanding>
<bntc:GoingConcernDisclosureTextBlock id="Factid_15686792" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared in conformity with US&amp;#160;GAAP, which contempla&lt;div style="display:inline;"&gt;t&lt;/div&gt;e continuation of the Company as a going concern. For the three months ended September&amp;#160;30, 2020, and 2019, the Company incurred a net loss of $2.7&amp;#160;million and&amp;#160;$1.1&amp;#160;million, and used net cash of $2.3&amp;#160;million and $0.5&amp;#160;million in operations, respectively. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on the existing cash and cash equivalents of the Company, including the proceeds from a public offering of common stock (and common stock equivalents) that closed on October&amp;#160;6, 2020 (see Note 1&lt;div style="display:inline;"&gt;3&lt;/div&gt;), management estimates that cash and cash equivalents will be sufficient to fund the Company&amp;#8217;s operations for at least the next twelve months from the filing of this form&amp;#160;10-Q.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial report does not contain any adjustments to the amounts or classifications of recorded assets or liabilities that might be necessary if the Company does not continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The financial statements take no account of the consequences, if any, of the effects of unsuccessful product development or commercialization, nor of the inability of the Company to obtain adequate funding in the future. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:GoingConcernDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock id="Factid_15696321" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="display:inline;"&gt;3&lt;/div&gt;. Subsequent events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On October&amp;#160;6, 2020, the Company announced the closing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;offering price. The&lt;/div&gt; total offering of 3,709,676 shares of common stock and common stock equivalents consisted of 2,666,644 firm shares of common stock, 483,870 shares of common stock purchased under the underwriter&amp;#8217;s over-allotment options and 559,162 shares of common stock underlying &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share. The Company received gross proceeds of approximately $11.5&amp;#160;million and net proceeds of approximately $9.9&amp;#160;million from the offering.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&amp;#8220;COVID-19&amp;#8221;)&lt;/div&gt; on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company did experience some disruption from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; including disruption of the timing and completion of certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials we are unable to predict the overall impact that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; will have on our financial position and operating results due to numerous uncertainties.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Factid_15696322" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="display:inline;"&gt;2&lt;/div&gt;. Commitments and contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contract commitments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock id="Factid_15696323" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="display:inline;"&gt;1&lt;/div&gt;. Income taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three months ended September&amp;#160;30, 2020, and 2019, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is&amp;#160;more likely than not that the benefit will be realized. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Factid_15696348" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;. Stockholders&amp;#8217; equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to warrants during for the three months ended&amp;#160;September 30, 2020,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:74%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Common&lt;br/&gt; Stock&amp;#160;from&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&amp;#160;(per&amp;#160;share)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;145,421&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;29.48&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(38,326&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;82.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding and exercisable at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;107,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;br/&gt; &lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Share Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Upon the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; the Company assumed BBL&amp;#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; pursuant to the Benitec Officers&amp;#8217; and Employees&amp;#8217; Share Option Plan (the &amp;#8220;Plan&amp;#8221;). This includes the Company&amp;#8217;s assumption of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; no new options have been or will be issued under the Plan. Current options on issue are under the BBL plan. From time to time, BBL issued employee&amp;#8217;s options to acquire shares in the Company at a fixed price. Each option when exercised entitles the option holder to one share of common stock of the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder. Employee options vest one third on each anniversary for three years. If an employee leaves the Company, they have 90 days to exercise their options or the options are cancelled.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Equity Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to equity awards, which comprised of stock options during the&amp;#160;three months&amp;#160;ended September&amp;#160;30, 2020,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:60%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Stock&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt; Remaining&lt;br/&gt; Contractual&amp;#160;Term&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Aggregate&lt;br/&gt; Intrinsic&amp;#160;Value&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;70,161&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60.42&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.89&amp;#160;years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(444&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69.32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;69,717&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60.00&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.65 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;43,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;68.53&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2.26 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The classification of share-based compensation expense for the three months ended: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:83%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;72&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;38&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of&amp;#160;September 30, 2020, there was $119,000 of unrecognized share-based compensation expense related to stock options issued under the Share Plan. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Factid_15696349" contextRef="P07_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to warrants during for the three months ended&amp;#160;September 30, 2020,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:74%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Common&lt;br/&gt; Stock&amp;#160;from&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&amp;#160;(per&amp;#160;share)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at July&amp;#160;1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;145,421&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;29.48&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(38,326&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;82.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding and exercisable at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;107,095&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;10.50&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock id="Factid_15696354" contextRef="P07_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The activity related to equity awards, which comprised of stock options during the&amp;#160;three months&amp;#160;ended September&amp;#160;30, 2020,&amp;#160;is summarized as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:60%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:4%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Stock&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Weighted-&lt;br/&gt; average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average&lt;/div&gt;&lt;br/&gt; Remaining&lt;br/&gt; Contractual&amp;#160;Term&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;Aggregate&lt;br/&gt; Intrinsic&amp;#160;Value&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at June&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;70,161&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60.42&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.89&amp;#160;years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(444&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69.32&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Outstanding at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;69,717&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;60.00&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;2.65 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at September&amp;#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;43,273&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;68.53&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;2.26 years&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock id="Factid_15696355" contextRef="P07_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The classification of share-based compensation expense for the three months ended: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:83%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:6%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;(17&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;29&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;72&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total share-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;38&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;55&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:LesseeOperatingLeasesTextBlock id="Factid_15696365" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="display:inline;"&gt;9&lt;/div&gt;. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&amp;#8217;s lease does not contain any residual value guarantees or material restrictive covenants. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2020, the Company&amp;#8217;s operating lease has a remaining lease term of 1.7 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;September&amp;#160;30,&amp;#160;2020&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;156&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;218&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;375&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(16&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;359&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recorded lease liabilities and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&amp;#8217;s incremental borrowing rate. Rent expense under the lease $52,000 for both the three months ended September&amp;#160;30, 2020 and 2019, respectively, and was recorded in the general and administrative expenses.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock id="Factid_15696366" contextRef="P07_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&amp;#160;30, 2020, the Company&amp;#8217;s operating lease has a remaining lease term of 1.7 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:80%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;September&amp;#160;30,&amp;#160;2020&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;156&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;218&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total operating lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;375&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;(16&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Present value of operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;359&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="Factid_15696371" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="display:inline;"&gt;8&lt;/div&gt;. Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Trade payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;299&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;282&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued license fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;171&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;54&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;43&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;155&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;111&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;250&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;624&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;741&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock id="Factid_15696372" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Trade payable&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;299&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;282&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued license fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;171&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;54&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Accrued professional fees&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;43&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;155&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other payables&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;111&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;250&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;624&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#160;741&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="Factid_15696385" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;. Property and equipment, net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(255, 255, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;1,283&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;1,109&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,344&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,170&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;(841&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;(796&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;503&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;374&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense was $45,000 and $51,000 for the three months ended September&amp;#160;30, 2020 and 2019, respectively. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock id="Factid_15696386" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%;;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;11&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(255, 255, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lab equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;1,283&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;1,109&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer hardware&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;26&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;24&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,344&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;1,170&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated depreciation and amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;(841&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;"&gt;(796&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;)&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total property and equipment, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;503&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;374&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:OtherAssetsDisclosureTextBlock id="Factid_15696418" contextRef="P07_01_2020To09_30_2020">&lt;div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="display:inline;"&gt;6&lt;/div&gt;. Other assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;564&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;861&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Security deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;14&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market value of listed shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;588&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;949&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
<us-gaap:ScheduleOfOtherAssetsTableTextBlock id="Factid_15696420" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;564&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;861&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Security deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;14&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;69&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Other deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;18&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market value of listed shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;1&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;588&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;949&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
<us-gaap:CashAndCashEquivalentsDisclosureTextBlock id="Factid_15696445" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Cash and Cash equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash at Bank&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,450&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,231&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term Deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,570&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,450&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,801&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock id="Factid_15696446" contextRef="P07_01_2020To09_30_2020">&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: 'times new roman';;width:76%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(US$&amp;#8217;000)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&amp;#160;30,&lt;br/&gt; 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Cash at Bank&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,450&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;5,231&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term Deposit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;4,570&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;7,450&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;9,801&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-size: 1px;"&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock id="Factid_15696447" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Benitec Biopharma Inc. (the &amp;#8220;Company&amp;#8221;) is a corporation formed under the laws of Delaware, United States, on November&amp;#160;22, 2019. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&amp;#8220;BBL&amp;#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&amp;#160;15, 2020. On August&amp;#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&amp;#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DNA-directed&lt;/div&gt; RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On November&amp;#160;27, 2019, BBL announced its intention to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domicile&lt;/div&gt; from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; acquired all BBL shares and BBL became a wholly-owned &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;subsidiary of Benitec Biopharma Inc. BBL shareholders &lt;/div&gt; received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL&amp;#8217;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company&amp;#8217;s common stock for every three ADSs held. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; was completed on April&amp;#160;15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March&amp;#160;26, 2020 and by the Supreme Court of Queensland on March&amp;#160;30, 2020.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the U.S. Securities and Exchange Commission&amp;#8217;s (&amp;#8220;SEC&amp;#8221;) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company&amp;#8217;s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July&amp;#160;1, 2019. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;BBL announced that the transaction to redomicile from A&lt;div style="display:inline;"&gt;u&lt;/div&gt;stralia to the United States was fully implemented on April&amp;#160;15, 2020. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; was approved by BBL shareholders at a Scheme Meeting held on March&amp;#160;26, 2020 and confirmed by the Supreme Court of Queensland on March&amp;#160;30, 2020.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The terms the &amp;#8220;Company,&amp;#8221; &amp;#8220;we,&amp;#8221; &amp;#8220;us,&amp;#8221; &amp;#8220;our&amp;#8221; and similar terms used in refer (i), prior to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation&lt;/div&gt; to BBL, an Australian corporation, and its subsidiaries, and (ii), following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-domiciliation,&lt;/div&gt; to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Biopharma Inc.&amp;#160;is listed on the Nasdaq Capital Market LLC (&amp;#8220;Nasdaq&amp;#8221;) under the symbol &amp;#8220;BNTC&amp;#8221;, and Benitec Biopharma Inc. is subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBL became a wholly owned subsidiary of Benitec Biopharma Inc. and delisted from the ASX on April&amp;#160;15, 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s fiscal year end is June 30. References to a particular &amp;#8220;fiscal year&amp;#8221; are to our fiscal year end&amp;#160;June&amp;#160;30 of that calendar year. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:74%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principal&amp;#160;place&lt;br/&gt; of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;business/country&lt;br/&gt; of incorporation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ownership&lt;br/&gt; Fiscal&lt;br/&gt; Year 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ownership&lt;br/&gt; Fiscal&lt;br/&gt; Year 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&amp;#8220;BBL&amp;#8221;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;United&lt;br/&gt; Kingdom&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;br/&gt; &amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<bntc:ScheduleOfEntitiesInControlTableTextBlock id="Factid_15696448" contextRef="P07_01_2020To09_30_2020">&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;width:74%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;;vertical-align:bottom;;width:5%;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principal&amp;#160;place&lt;br/&gt; of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;business/country&lt;br/&gt; of incorporation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ownership&lt;br/&gt; Fiscal&lt;br/&gt; Year 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Ownership&lt;br/&gt; Fiscal&lt;br/&gt; Year 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Biopharma Proprietary Limited (&amp;#8220;BBL&amp;#8221;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec Australia Proprietary Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;Australia&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec Limited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;United&lt;br/&gt; Kingdom&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;br/&gt; &amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benitec, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Benitec LLC&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNAi Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman';;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap;;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="background-color: rgb(204, 238, 255);;vertical-align:top;"&gt;&lt;div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;"&gt;Tacere Therapeutics, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;USA&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;times new roman&amp;quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;"&gt;100&lt;/td&gt;&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;"&gt;%&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:ScheduleOfEntitiesInControlTableTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock id="Factid_15696449" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation and Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&amp;#8220;GAAP&amp;#8221;)&amp;#160;for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of SEC Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and accompanying notes included in the Company&amp;#8217;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June&amp;#160;30, 2020.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&amp;#8217;s consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&amp;#8217;s future results of operations will be affected.&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). This is the source of authoritative US&amp;#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s functional currency and reporting currency is the United States dollar. &lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBL&amp;#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&amp;#8217; equity as &amp;#8220;Accumulated other comprehensive income (loss).&amp;#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss).&lt;/div&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its financial assets and liabilities in accordance with US&amp;#160;GAAP using ASC 820, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;1:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;2:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;3:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&amp;#8217;s cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of September&amp;#160;30, 2020, and June&amp;#160;30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;;margin-left :auto;margin-right :auto;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&amp;#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:6%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:17%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Lab equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Computer hardware&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&amp;#8217;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i)&amp;#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&amp;#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basic and Diluted Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&amp;#160;30, 2020, and 2019, there were 145,421 and 65,852 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive.&lt;/div&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company adopted ASC 606 &amp;#8211; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#8220;ASC 606&amp;#8221;) on July&amp;#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&amp;#8217;s subsequent sales of product occurs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Government Research and Development Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant income is generated through the Australian federal government&amp;#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;eligible research and development expenditures. This grant is available for the Company&amp;#8217;s research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to the Company&amp;#8217;s activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be claiming the Australian Government research and development grants going forward. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Pre-clinical a&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;nd clinical&lt;/div&gt; development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company adopted FASB Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07&lt;/div&gt; and accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For uncertain tax positions that meet a &amp;#8220;more likely than not&amp;#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&amp;#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive loss.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&amp;#160;2016-13:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments &amp;#8211; Credit Losses&lt;/div&gt; (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&amp;#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&amp;#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&amp;#8220;SRC&amp;#8221;) as of November&amp;#160;15, 2019. As such, ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-10:&lt;/div&gt; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates&lt;/div&gt; amended the effective date for the Company to be for reporting periods beginning after December&amp;#160;15, 2022. The Company will adopt this ASU effective July&amp;#160;1, 2023.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<bntc:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock id="Factid_15696450" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basis of Presentation and Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&amp;#8217;s consolidated financial statements contained in this Quarterly Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; have been prepared in accordance with generally accepted accounting principles in the U.S. (&amp;#8220;GAAP&amp;#8221;)&amp;#160;for interim financial information and with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 10 of SEC Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X.&lt;/div&gt; Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and accompanying notes included in the Company&amp;#8217;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the year ended June&amp;#160;30, 2020.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The preparation of the Company&amp;#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&amp;#8217;s consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&amp;#8217;s future results of operations will be affected.&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Reference is frequently made herein to the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). This is the source of authoritative US&amp;#160;GAAP recognized by the FASB to be applied to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-governmental&lt;/div&gt; entities.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
<us-gaap:ConsolidationPolicyTextBlock id="Factid_15696451" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:SegmentReportingPolicyPolicyTextBlock id="Factid_15696452" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Segment Reporting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="Factid_15696453" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Foreign Currency Translation and Other Comprehensive Income (Loss) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&amp;#8217;s functional currency and reporting currency is the United States dollar. &lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BBL&amp;#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&amp;#8217; equity as &amp;#8220;Accumulated other comprehensive income (loss).&amp;#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss).&lt;/div&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="Factid_15696454" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its financial assets and liabilities in accordance with US&amp;#160;GAAP using ASC 820, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Fair Value Measurements.&lt;/div&gt; For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;1:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;2:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"&gt;&lt;tr style="page-break-inside: avoid;"&gt;&lt;td style="width:4%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;;width:8%;"&gt;Level&amp;#160;3:&lt;/td&gt;&lt;td style="text-align:left;;vertical-align:top;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px;"&gt;&lt;/div&gt;&lt;div style="clear: both; max-height: 0px; background: none;"&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&amp;#8217;s cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of September&amp;#160;30, 2020, and June&amp;#160;30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Factid_15696455" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:ConcentrationRiskCreditRisk id="Factid_15696456" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Concentrations of Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy id="Factid_15696457" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and Other Receivables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; experience. The Company&amp;#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="Factid_15696458" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"&gt;&lt;tr style="font-size: 0px;"&gt;&lt;td style="width:6%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:17%;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;;width:1%;"&gt;&lt;/td&gt;&lt;td style="width:75%;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Software&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-4&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Lab equipment&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Computer hardware&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"&gt;&lt;td style="vertical-align:top;"&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;shorter of the lease term or estimated useful lives&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="Factid_15696459" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&amp;#8217;s expected future discounted cash flows or market value, if readily determinable. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<bntc:TradeAndOtherPayablesPolicyTextBlock id="Factid_15696460" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Trade and other payables &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:TradeAndOtherPayablesPolicyTextBlock>
<us-gaap:LesseeLeasesPolicyTextBlock id="Factid_15696461" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;After lease commencement, the Company measures its leases as follows: (i)&amp;#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&amp;#160;the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock id="Factid_15696462" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Basic and Diluted Net Income (Loss) Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&amp;#160;30, 2020, and 2019, there were 145,421 and 65,852 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive.&lt;/div&gt;&lt;div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock id="Factid_15696463" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company adopted ASC 606 &amp;#8211; &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers &lt;/div&gt;(&amp;#8220;ASC 606&amp;#8221;) on July&amp;#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 1: Identify the contract(s) with a customer. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 2: Identify the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 3: Determine the transaction price. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Management has also made the judgement that the grant of the license and transfer of associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Licensing revenues &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Royalties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from licensees of the Company&amp;#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&amp;#8217;s subsequent sales of product occurs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Services revenue &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<bntc:GovernmentResearchAndDevelopmentGrantsPolicyTextBlock id="Factid_15696464" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Government Research and Development Grants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant income is generated through the Australian federal government&amp;#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;eligible research and development expenditures. This grant is available for the Company&amp;#8217;s research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to the Company&amp;#8217;s activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will not be claiming the Australian Government research and development grants going forward. &lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bntc:GovernmentResearchAndDevelopmentGrantsPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy id="Factid_15696465" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-clinical&lt;/div&gt; trials. &lt;div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Pre-clinical a&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;nd clinical&lt;/div&gt; development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Factid_15696466" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Equity-based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company records share-based compensation in accordance with ASC 718, &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Stock Compensation&lt;/div&gt;. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based compensation at fair value using the Black-Scholes Option Pricing Model.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company adopted FASB Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-07&lt;/div&gt; and accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt; share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:IncomeTaxPolicyTextBlock id="Factid_15696467" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 &lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Accounting for Income Taxes&lt;/div&gt;, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For uncertain tax positions that meet a &amp;#8220;more likely than not&amp;#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&amp;#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="Factid_15696468" contextRef="P07_01_2020To09_30_2020">&lt;div style="font-family: &amp;quot;times new roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;;font-style:italic;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-owner&lt;/div&gt; sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive loss.&lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:PaymentsOfStockIssuanceCosts id="Factid_15710231" contextRef="P07_01_2019To09_30_2019" unitRef="Unit_USD" decimals="-3">480000</us-gaap:PaymentsOfStockIssuanceCosts>
<xbrli:unit id="Unit_USD">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Unit_USD_per_Share">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended" />
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bntc-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<schema targetNamespace="http://www.benitecbiopharmainc.com/20200930" elementFormDefault="qualified" xmlns:bntc="http://www.benitecbiopharmainc.com/20200930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Business" id="Business">
<link:definition>1008 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" id="GoingConcern">
<link:definition>1010 - Disclosure - Going concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Revenue" id="Revenue">
<link:definition>1011 - Disclosure - Revenue</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
<link:definition>1012 - Disclosure - Cash and Cash equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" id="OtherAssets">
<link:definition>1013 - Disclosure - Other assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1014 - Disclosure - Property and equipment, net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
<link:definition>1015 - Disclosure - Trade and other payables</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/Leases" id="Leases">
<link:definition>1016 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1017 - Disclosure - Stockholders' equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1018 - Disclosure - Income taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1019 - Disclosure - Commitments and contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1020 - Disclosure - Subsequent events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" id="BusinessTables">
<link:definition>1022 - Disclosure - Business (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" id="RevenueTables">
<link:definition>1023 - Disclosure - Revenue (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
<link:definition>1024 - Disclosure - Cash and Cash equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" id="OtherAssetsTables">
<link:definition>1025 - Disclosure - Other assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1026 - Disclosure - Property and equipment, net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
<link:definition>1027 - Disclosure - Trade and other payables (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" id="LeasesTables">
<link:definition>1028 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1029 - Disclosure - Stockholders' equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" id="BusinessSummaryOfEntitiesInControlDetail">
<link:definition>1030 - Disclosure - Business - Summary of entities in control (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" id="BusinessAdditionalInformationDetail">
<link:definition>1031 - Disclosure - Business - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<link:definition>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" id="GoingConcernAdditionalInformationDetail">
<link:definition>1034 - Disclosure - Going concern - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" id="RevenueSummaryOfRevenueFromCustomersDetail">
<link:definition>1035 - Disclosure - Revenue - Summary of revenue from customers (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" id="RevenueSummaryOfDisaggregationOfRevenueDetail">
<link:definition>1036 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" id="CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<link:definition>1037 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" id="OtherAssetsSummaryOfOtherAssetsDetail">
<link:definition>1038 - Disclosure - Other assets - Summary of other assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" id="PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<link:definition>1039 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Property and equipment, net - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" id="TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<link:definition>1041 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<link:definition>1042 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1043 - Disclosure - Leases - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" id="StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<link:definition>1044 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" id="StockholdersEquityScheduleOfEquityAwardsDetail">
<link:definition>1045 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" id="StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1046 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Stockholders' equity - Additional information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1048 - Disclosure - Subsequent events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="bntc-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
<import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
<element name="RoyaltiesAndLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_RoyaltiesAndLicenseFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AmortizationOfRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_AmortizationOfRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreasedecreaseInAccountsAndOtherPayables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreasedecreaseInAccountsAndOtherPayables" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_IncreaseDecreaseInLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScheduleOfEntitiesInControlAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="GoingConcernDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GoingConcernDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TradeAndOtherPayablesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_TradeAndOtherPayablesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfEntitiesInControlTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfEntitiesInControlLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_ScheduleOfEntitiesInControlLineItems" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedBblMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedBblMember" substitutionGroup="xbrli:item" />
<element name="BenitecAustraliaProprietaryLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecAustraliaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLimitedMember" substitutionGroup="xbrli:item" />
<element name="BenitecIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecIncMember" substitutionGroup="xbrli:item" />
<element name="RnaiTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_RnaiTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="TacereTherapeuticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_TacereTherapeuticsIncMember" substitutionGroup="xbrli:item" />
<element name="BenitecLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecLlcMember" substitutionGroup="xbrli:item" />
<element name="BenitecBiopharmaProprietaryLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_BenitecBiopharmaProprietaryLimitedMember" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesRedomiciliationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CommonStockSharesRedomiciliationDescription" substitutionGroup="xbrli:item" />
<element name="LabEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_SummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="FinancialAssetsAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_FinancialAssetsAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GrantReceivableOnResearchAndDevelopmentExpendituresMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" substitutionGroup="xbrli:item" />
<element name="Otherdeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_Otherdeposits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MarketValueOfListedShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_MarketValueOfListedShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedLicenceFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_AccruedLicenceFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantsOrRightsGrantsInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsGrantsInPeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsExcercisedDuringThePeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" substitutionGroup="xbrli:item" />
<element name="WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" substitutionGroup="xbrli:item" />
<element name="CommonStockEquivalents" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_CommonStockEquivalents" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromIssueOfStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="bntc_GrossProceedsFromIssueOfStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreFundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="bntc_PreFundedWarrantsMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bntc-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DepositAssets" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_BNTC_RoyaltiesAndLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_BNTC_RoyaltiesAndLicenseFees" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="15" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreasedecreaseInAccountsAndOtherPayables" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_IncreaseDecreaseInLeaseLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_BNTC_AmortizationOfRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_BNTC_AmortizationOfRightOfUseAssets" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="18" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_DueFromBanks" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_SecurityDeposit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_Otherdeposits" xlink:label="loc_BNTC_Otherdeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_BNTC_Otherdeposits" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_BNTC_MarketValueOfListedShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_BNTC_MarketValueOfListedShares" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_BNTC_AccruedLicenceFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_BNTC_AccruedLicenceFeesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="2" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bntc-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueSummaryOfDisaggregationOfRevenueDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_StatementTable_747523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525_default" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StatementTable_747147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747909" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" xlink:to="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_747935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_747935" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_RoyaltyMember_747417" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_ServiceMember_747418" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747361" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_StatementTable_747358" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_747367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_747367" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_747368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredOverTimeMember_747368" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_srt_ProductOrServiceAxis_747665" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_LicenseMember_747667" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_RoyaltyMember_747668" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_ServiceMember_747669" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_StatementTable_748057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_770058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_770058" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_748016" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_748015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_748015" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_748019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_TypeOfArrangementAxis_748019" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_748439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_748439" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_StatementTable_768325" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_770073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_OverAllotmentOptionMember_770073" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_CommonStockEquivalents" xlink:label="loc_bntc_CommonStockEquivalents_770080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CommonStockEquivalents_770080" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GrossProceedsFromIssueOfStock" xlink:label="loc_bntc_GrossProceedsFromIssueOfStock_770082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_GrossProceedsFromIssueOfStock_770082" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" use="optional" order="13" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bntc-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" xlink:type="locator"/>
    <label xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <label xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" xlink:type="locator"/>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <label xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <label xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</label>
    <label xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <label xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</label>
    <label xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" xlink:type="locator"/>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" xlink:type="locator"/>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <label xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" xlink:type="locator"/>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <label xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <label xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <label xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal place of business/country of incorporation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" xlink:type="locator"/>
    <label xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" xlink:type="locator"/>
    <label xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:type="locator"/>
    <label xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee benefits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, less current portion</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</label>
    <label xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value&#x2014;10,000,000 shares authorized; 1,108,374 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</label>
    <label xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposit Assets</label>
    <label xlink:label="lab_us-gaap_DepositAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deposits</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositAssets" xlink:to="lab_us-gaap_DepositAssets" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</label>
    <label xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <label xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <label xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Par Value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Shares Authorized</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Issued</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from customers</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:type="resource" xml:lang="en-US">Revenues from customers</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:type="resource" xml:lang="en-US">Disaggregated revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</label>
    <label xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees" xlink:type="locator"/>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties And License Fees</label>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and license fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RoyaltiesAndLicenseFees" xlink:to="lab_bntc_RoyaltiesAndLicenseFees" xlink:type="arc"/>
    <label xlink:label="lab_bntc_RoyaltiesAndLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties and license fees</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</label>
    <label xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (loss), net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investment</label>
    <label xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (loss), net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency translation gain (loss)</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation loss (Gain)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</label>
    <label xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning (In shares)</label>
    <label xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end (In shares)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold for cash, net of offering costs of $240</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock sold for cash, net of offering costs of $240, Shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited</label>
    <label xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeiture of share-based payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance and exercise of prefunded warrants net of transaction costs</label>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants, net of transaction costs of $240</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:to="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance and exercise of pre-funded warrants, net of transaction costs.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <label xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments For Stock Issuance Costs</label>
    <label xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share issue transaction costs</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash from operating activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Right of Use Assets</label>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AmortizationOfRightOfUseAssets" xlink:to="lab_bntc_AmortizationOfRightOfUseAssets" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AmortizationOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade and other receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Accounts and Other Payables</label>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:to="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accounts and other payables.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee benefit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:type="locator"/>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease In Lease Liabilities</label>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc"/>
    <label xlink:label="lab_bntc_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease In lease liabilities.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in provided by operations</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property and equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided in (used in) investing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issues of shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Initial measurement of operating lease right-of-use assets and liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract" xlink:to="lab_bntc_ScheduleOfEntitiesInControlAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GoingConcernAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernAbstract" xlink:to="lab_bntc_GoingConcernAbstract" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GoingConcernAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Going concern</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Going Concern Disclosure [Text Block]</label>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going concern</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GoingConcernDisclosureTextBlock" xlink:to="lab_bntc_GoingConcernDisclosureTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GoingConcernDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Going concern disclosure.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsAbstract" xlink:to="lab_us-gaap_OtherAssetsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subsequent events</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Other Comprehensive Income (Loss)</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Risk</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and Other Receivables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables [Policy Text Block]</label>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:to="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trade and other payables.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leases</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Income (Loss) Per Share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants [Policy Text Block]</label>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:to="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Research and Development Grants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity-based Compensation Expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="loc_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Use of Estimates [Policy Text Block]</label>
    <label xlink:label="lab_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Use of Estimates</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="lab_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Use of Estimates.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Table Text Block]</label>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of entities in control</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of entities in control.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of revenue from customers</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of disaggregation of revenue</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of cash and cash equivalent</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of other assets</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of property and equipment net</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of trade and other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of maturities of the operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of warrants or rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of equity awards</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share-basedcompensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable" xlink:to="lab_bntc_ScheduleOfEntitiesInControlTable" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ScheduleOfEntitiesInControlLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Entities In Control [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems" xlink:to="lab_bntc_ScheduleOfEntitiesInControlLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited BBL [Member]</label>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited ("BBL") [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Australia Proprietary Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecAustraliaProprietaryLimitedMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLimitedMember" xlink:to="lab_bntc_BenitecLimitedMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Inc [Member]</label>
    <label xlink:label="lab_bntc_BenitecIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecIncMember" xlink:to="lab_bntc_BenitecIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RNAi Therapeutics Inc [Member]</label>
    <label xlink:label="lab_bntc_RnaiTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RNAi Therapeutics, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_RnaiTherapeuticsIncMember" xlink:to="lab_bntc_RnaiTherapeuticsIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_TacereTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tacere Therapeutics Inc [Member]</label>
    <label xlink:label="lab_bntc_TacereTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tacere Therapeutics, Inc. [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_TacereTherapeuticsIncMember" xlink:to="lab_bntc_TacereTherapeuticsIncMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec LLC [Member]</label>
    <label xlink:label="lab_bntc_BenitecLlcMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec LLC [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecLlcMember" xlink:to="lab_bntc_BenitecLlcMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
    <label xlink:label="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Benitec Biopharma Proprietary Limited [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:to="lab_bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:type="arc"/>
    <loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" xlink:type="locator"/>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
    <label xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation Date Of Incorporation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_CommonStockSharesRedomiciliationDescription" xlink:label="loc_bntc_CommonStockSharesRedomiciliationDescription" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Redomiciliation Description</label>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Re-domiciliation Description</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommonStockSharesRedomiciliationDescription" xlink:to="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CommonStockSharesRedomiciliationDescription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, shares, re-domiciliation description.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <label xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member]</label>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_LabEquipmentMember" xlink:to="lab_bntc_LabEquipmentMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab Equipment [Member].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <label xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</label>
    <label xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</label>
    <label xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" xlink:type="locator"/>
    <label xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies [Table].</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <label xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc"/>
    <label xlink:label="lab_bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies [Line Items].</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue" xlink:type="locator"/>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets At Fair Value</label>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_FinancialAssetsAtFairValue" xlink:to="lab_bntc_FinancialAssetsAtFairValue" xlink:type="arc"/>
    <label xlink:label="lab_bntc_FinancialAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial assets at fair value.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</label>
    <label xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Receivable on research and development expenditures [Member]</label>
    <label xlink:label="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Receivable on research and development expenditures [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:to="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Receivable on research and development expenditures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</label>
    <label xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing revenue [Member]</label>
    <label xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</label>
    <label xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenue [Member]</label>
    <label xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</label>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue [Member]</label>
    <label xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Development Activities [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</label>
    <label xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services transferred at a point in time [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</label>
    <label xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Services transferred over time [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_DueFromBanks" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Banks</label>
    <label xlink:label="lab_us-gaap_DueFromBanks" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash at Bank</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromBanks" xlink:to="lab_us-gaap_DueFromBanks" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Deposits, at Carrying Value</label>
    <label xlink:label="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term Deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimeDepositsAtCarryingValue" xlink:to="lab_us-gaap_TimeDepositsAtCarryingValue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</label>
    <label xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_Otherdeposits" xlink:label="loc_bntc_Otherdeposits" xlink:type="locator"/>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OtherDeposits</label>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other deposit</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_Otherdeposits" xlink:to="lab_bntc_Otherdeposits" xlink:type="arc"/>
    <label xlink:label="lab_bntc_Otherdeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other deposits.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares" xlink:type="locator"/>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market value Of listed shares</label>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market value of listed shares</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_MarketValueOfListedShares" xlink:to="lab_bntc_MarketValueOfListedShares" xlink:type="arc"/>
    <label xlink:label="lab_bntc_MarketValueOfListedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market value of listed shares.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</label>
    <label xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</label>
    <label xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, gross</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <label xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other payables</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent" xlink:type="locator"/>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Licence Fees Current</label>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued license fees</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_AccruedLicenceFeesCurrent" xlink:to="lab_bntc_AccruedLicenceFeesCurrent" xlink:type="arc"/>
    <label xlink:label="lab_bntc_AccruedLicenceFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued licence fees current.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease has a remaining lease term</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease discount rate</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Grants In Period</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights grants in period.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Excercised During The Period</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:to="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights excercised during the period.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:label="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Rights Cashless Exercise Of Warrants</label>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:to="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of warrants or rights cashless exercise of warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Rights Outstanding</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercise price of class of warrants or rights outstanding</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercise price of class of warrants or rights outstanding and excercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or rights outstanding.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Granted During The Period</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or granted during the period.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Exercised During The Period</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted - average exercise price of class of warrants or exercised during the period.</label>
    <loc xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:type="locator"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average Exercise Price Of Class Of Warrants Or Exercised During The Period Cash Less Exercise Of Warrants</label>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:to="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:type="arc"/>
    <label xlink:label="lab_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price of class of warrants or exercised during the period cash less exercise of warrants.</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock Options,Outstanding, beginning of period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Exercisable, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Exercise price, beginning of period</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Exercise price, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Forfeited</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Exercise Price, Exercisable, end of period</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <label xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock option</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognised share based compensation expense</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock issue price per share</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_CommonStockEquivalents" xlink:label="loc_bntc_CommonStockEquivalents" xlink:type="locator"/>
    <label xlink:label="lab_bntc_CommonStockEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Equivalents</label>
    <label xlink:label="lab_bntc_CommonStockEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">common stock equivalents</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_CommonStockEquivalents" xlink:to="lab_bntc_CommonStockEquivalents" xlink:type="arc"/>
    <label xlink:label="lab_bntc_CommonStockEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock equivalents</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_GrossProceedsFromIssueOfStock" xlink:label="loc_bntc_GrossProceedsFromIssueOfStock" xlink:type="locator"/>
    <label xlink:label="lab_bntc_GrossProceedsFromIssueOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issue Of Stock</label>
    <label xlink:label="lab_bntc_GrossProceedsFromIssueOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from issue of stock</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_GrossProceedsFromIssueOfStock" xlink:to="lab_bntc_GrossProceedsFromIssueOfStock" xlink:type="arc"/>
    <label xlink:label="lab_bntc_GrossProceedsFromIssueOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross proceeds from issue of stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</label>
    <label xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc"/>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:type="locator"/>
    <label xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <label xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc"/>
    <loc xlink:href="bntc-20200930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember" xlink:type="locator"/>
    <label xlink:label="lab_bntc_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre Funded Warrants [Member]</label>
    <label xlink:label="lab_bntc_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded warrants [Member]</label>
    <labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bntc_PreFundedWarrantsMember" xlink:to="lab_bntc_PreFundedWarrantsMember" xlink:type="arc"/>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bntc-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-November-2020 [05:22:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CoverPage" roleURI="http://www.benitecbiopharmainc.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedBalanceSheets" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Business" roleURI="http://www.benitecbiopharmainc.com/role/Business" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#GoingConcern" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcern" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Revenue" roleURI="http://www.benitecbiopharmainc.com/role/Revenue" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalents" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssets" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssets" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNet" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#Leases" roleURI="http://www.benitecbiopharmainc.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquity" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#IncomeTaxes" roleURI="http://www.benitecbiopharmainc.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CommitmentsAndContingencies" roleURI="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#SubsequentEvents" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessTables" roleURI="http://www.benitecbiopharmainc.com/role/BusinessTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueTables" roleURI="http://www.benitecbiopharmainc.com/role/RevenueTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalentsTables" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssetsTables" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayablesTables" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesTables" roleURI="http://www.benitecbiopharmainc.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityTables" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessSummaryOfEntitiesInControlDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BusinessAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#GoingConcernAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueSummaryOfRevenueFromCustomersDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#RevenueSummaryOfDisaggregationOfRevenueDetail" roleURI="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" roleURI="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#OtherAssetsSummaryOfOtherAssetsDetail" roleURI="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" roleURI="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityScheduleOfWarrantsOrRightsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityScheduleOfEquityAwardsDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="bntc-20200930.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_747112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_747113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentType_747113" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_747125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_AmendmentFlag_747125" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_767989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentQuarterlyReport_767989" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_747252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentTransitionReport_747252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_747133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFileNumber_747133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_747131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityRegistrantName_747131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_747126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentPeriodEndDate_747126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_747127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalYearFocus_747127" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_747128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_DocumentFiscalPeriodFocus_747128" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_747132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCentralIndexKey_747132" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_747136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CurrentFiscalYearEndDate_747136" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_747140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCurrentReportingStatus_747140" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_747120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityInteractiveDataCurrent_747120" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_747142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityFilerCategory_747142" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_747143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntitySmallBusiness_747143" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_747144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityEmergingGrowthCompany_747144" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_747151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityExTransitionPeriod_747151" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_747141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityShellCompany_747141" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_748327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_748327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_748405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressAddressLine1_748405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_747161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressCountry_747161" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_747162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityAddressPostalZipCode_747162" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_748406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_CityAreaCode_748406" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_748407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_LocalPhoneNumber_748407" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_747163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_Security12bTitle_747163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_747165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_TradingSymbol_747165" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_747166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_SecurityExchangeName_747166" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_747167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_747112" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_747167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_746977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_AssetsAbstract_746977" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_746978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrentAbstract_746978" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_746979" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_746980" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_746981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_746978" xlink:to="loc_us-gaap_OtherAssetsCurrent_746981" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_746983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_AssetsCurrent_746983" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_746985" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_746986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_DepositAssets_746986" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_746987" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_746988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_746977" xlink:to="loc_us-gaap_Assets_746988" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_748443" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_746991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_746991" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_746992" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746993" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_746991" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_746994" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_746995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesCurrent_746995" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_746999" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_747001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_Liabilities_747001" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_747005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_CommitmentsAndContingencies_747005" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_747013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquityAbstract_747013" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_747014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_CommonStockValue_747014" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_747015" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_747016" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_747013" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_747017" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_StockholdersEquity_747018" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_746989" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_747019" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_747035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_747045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_747045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_747047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesIssued_747047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_747049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747032" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_747049" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_747061" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_747061" xlink:to="loc_us-gaap_StatementTable_747523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_srt_ProductOrServiceAxis_747524" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747524" xlink:to="loc_srt_ProductsAndServicesDomain_747525" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747523" xlink:to="loc_us-gaap_StatementLineItems_747526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_RevenuesAbstract_747066" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747067" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_747069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747066" xlink:to="loc_us-gaap_Revenues_747069" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_747070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingExpensesAbstract_747070" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_RoyaltiesAndLicenseFees" xlink:label="loc_bntc_RoyaltiesAndLicenseFees_747072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_bntc_RoyaltiesAndLicenseFees_747072" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_747073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_747073" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_747074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_747074" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_747076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_747070" xlink:to="loc_us-gaap_OperatingExpenses_747076" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_747079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OperatingIncomeLoss_747079" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_747082" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_747083" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_747084" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747085" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_747086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_747081" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_747086" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_NetIncomeLoss_747099" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747092" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_747088" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_747094" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_747096" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_747098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareAbstract_747098" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_747098" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_747104" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747526" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_747105" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_747106" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747109" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747109" xlink:to="loc_us-gaap_StatementTable_747147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_747148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_747148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_747149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_747148" xlink:to="loc_us-gaap_ClassOfStockDomain_747149" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_747152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_747152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_747154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_747152" xlink:to="loc_us-gaap_EquityComponentDomain_747154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_747158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_CommonStockMember_747158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_747164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_747164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_747168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_RetainedEarningsMember_747168" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_747154" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_747169" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747147" xlink:to="loc_us-gaap_StatementLineItems_747150" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747171" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747172" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_747176" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_747178" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts" xlink:label="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts_748442" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_747173" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_747282" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_747174" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_NetIncomeLoss_747183" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_747184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_StockholdersEquity_747184" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_747185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747150" xlink:to="loc_us-gaap_SharesOutstanding_747185" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747220" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747220" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747223" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_747054" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetIncomeLoss_747025" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_747028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_747028" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_AmortizationOfRightOfUseAssets" xlink:label="loc_bntc_AmortizationOfRightOfUseAssets_747029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_bntc_AmortizationOfRightOfUseAssets_747029" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_747030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_747030" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_747031" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_747033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_747026" xlink:to="loc_us-gaap_ShareBasedCompensation_747033" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_747036" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_747037" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IncreasedecreaseInAccountsAndOtherPayables" xlink:label="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreasedecreaseInAccountsAndOtherPayables_747039" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_747040" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_747034" xlink:to="loc_bntc_IncreaseDecreaseInLeaseLiabilities_747041" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_747021" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747042" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_747043" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_747044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_747044" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_747022" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_747046" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_747048" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_747050" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_747023" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_747051" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_747053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_747053" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747055" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_747056" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747057" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_747054" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_747024" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_747058" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Business">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747235" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_747236" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747291" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747291" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_747294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747261" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GoingConcernDisclosureTextBlock" xlink:label="loc_bntc_GoingConcernDisclosureTextBlock_747262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747261" xlink:to="loc_bntc_GoingConcernDisclosureTextBlock_747262" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Revenue">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747296" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747296" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_747298" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747347" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_747353" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747424" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747424" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_747428" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747472" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_747473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747548" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747548" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_747549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747580" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747580" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_747581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747939" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747939" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_747940" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_747712" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_747713" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_747700" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_747701" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_747496" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_747497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_747496" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_747497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747292" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:label="loc_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_768319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_768319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_747299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_747299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_747300" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_747302" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_747303" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_747304" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_747305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_747305" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_747306" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_747307" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_747308" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_TradeAndOtherPayablesPolicyTextBlock" xlink:label="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_TradeAndOtherPayablesPolicyTextBlock_747309" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_747312" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_747314" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_747315" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock" xlink:label="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock_747317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock_747317" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_747318" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_747319" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_747320" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747292" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_747322" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessTables">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlTableTextBlock" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747237" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTableTextBlock_747238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747316" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_747330" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_747335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747316" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_747335" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747348" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_747356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747437" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747437" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_747440" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747477" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_747479" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747553" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747553" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_747555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747587" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747587" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_747591" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747942" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_747943" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_747945" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747942" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_747947" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlTable" xlink:label="loc_bntc_ScheduleOfEntitiesInControlTable_747241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747239" xlink:to="loc_bntc_ScheduleOfEntitiesInControlTable_747241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_747244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_747243" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_747244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedBblMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedBblMember_747245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecAustraliaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecAustraliaProprietaryLimitedMember_747246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecLimitedMember" xlink:label="loc_bntc_BenitecLimitedMember_747247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLimitedMember_747247" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecIncMember" xlink:label="loc_bntc_BenitecIncMember_747248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecIncMember_747248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecLlcMember" xlink:label="loc_bntc_BenitecLlcMember_747251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecLlcMember_747251" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_RnaiTherapeuticsIncMember" xlink:label="loc_bntc_RnaiTherapeuticsIncMember_747249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_RnaiTherapeuticsIncMember_747249" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_TacereTherapeuticsIncMember" xlink:label="loc_bntc_TacereTherapeuticsIncMember_747250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_TacereTherapeuticsIncMember_747250" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_BenitecBiopharmaProprietaryLimitedMember" xlink:label="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_747244" xlink:to="loc_bntc_BenitecBiopharmaProprietaryLimitedMember_747253" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlLineItems" xlink:label="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlTable_747241" xlink:to="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_749255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_dei_EntityIncorporationStateCountryCode_749255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlLineItems_747242" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_747255" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ScheduleOfEntitiesInControlAbstract" xlink:label="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_747257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_747257" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_CommonStockSharesRedomiciliationDescription" xlink:label="loc_bntc_CommonStockSharesRedomiciliationDescription_747258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_ScheduleOfEntitiesInControlAbstract_747240" xlink:to="loc_bntc_CommonStockSharesRedomiciliationDescription_747258" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747899" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747899" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747901" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_747903" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_LabEquipmentMember" xlink:label="loc_bntc_LabEquipmentMember_747905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_bntc_LabEquipmentMember_747905" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_747909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_747909" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_ComputerEquipmentMember_747911" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747902" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_747914" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_747916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_srt_RangeAxis_747916" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_747917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_747916" xlink:to="loc_srt_RangeMember_747917" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_747919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MinimumMember_747919" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_747918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_747917" xlink:to="loc_srt_MaximumMember_747918" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747900" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_747922" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747920" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_747923" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_747924" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_747924" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_747926" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_747927" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_747928" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_748421" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember" xlink:label="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_748422" xlink:to="loc_bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember_748423" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesTable_747925" xlink:to="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_FinancialAssetsAtFairValue" xlink:label="loc_bntc_FinancialAssetsAtFairValue_747932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_bntc_FinancialAssetsAtFairValue_747932" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_747933" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_747934" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_747935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_SummaryOfSignificantAccountingPoliciesLineItems_747929" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_747935" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GoingConcernAbstract" xlink:label="loc_bntc_GoingConcernAbstract_747274" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_747276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetIncomeLoss_747276" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bntc_GoingConcernAbstract_747274" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_747279" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_747399" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_747399" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_srt_ProductOrServiceAxis_747412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747412" xlink:to="loc_srt_ProductsAndServicesDomain_747413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_LicenseMember_747416" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_RoyaltyMember_747417" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747413" xlink:to="loc_us-gaap_ServiceMember_747418" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_747411" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_747414" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747419" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_747355" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_747358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_747355" xlink:to="loc_us-gaap_StatementTable_747358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_747362" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredAtPointInTimeMember" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_747367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_747367" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:label="loc_us-gaap_TransferredOverTimeMember_747368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_747363" xlink:to="loc_us-gaap_TransferredOverTimeMember_747368" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_747665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_srt_ProductOrServiceAxis_747665" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_747666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_747665" xlink:to="loc_srt_ProductsAndServicesDomain_747666" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_747667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_LicenseMember_747667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_747668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_RoyaltyMember_747668" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_747669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_747666" xlink:to="loc_us-gaap_ServiceMember_747669" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_747361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_747358" xlink:to="loc_us-gaap_StatementLineItems_747361" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_747361" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_747383" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromBanks" xlink:label="loc_us-gaap_DueFromBanks_747364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_DueFromBanks_747364" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimeDepositsAtCarryingValue" xlink:label="loc_us-gaap_TimeDepositsAtCarryingValue_747365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_TimeDepositsAtCarryingValue_747365" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_747350" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_747366" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaap_OtherAssetsAbstract_747453" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_747454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_747454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_747455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_SecurityDeposit_747455" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_Otherdeposits" xlink:label="loc_bntc_Otherdeposits_747457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_Otherdeposits_747457" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_MarketValueOfListedShares" xlink:label="loc_bntc_MarketValueOfListedShares_747458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_bntc_MarketValueOfListedShares_747458" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_747459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsAbstract_747453" xlink:to="loc_us-gaap_OtherAssetsCurrent_747459" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747480" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_747482" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_747484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_747484" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_747485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_EquipmentMember_747485" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_747487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_ComputerEquipmentMember_747487" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_747488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_747483" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_747488" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_747481" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_747490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_747491" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_747489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_747492" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_747494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_747493" xlink:to="loc_us-gaap_Depreciation_747494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_747565" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_747566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_747566" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_AccruedLicenceFeesCurrent" xlink:label="loc_bntc_AccruedLicenceFeesCurrent_747567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_bntc_AccruedLicenceFeesCurrent_747567" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_747569" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_747570" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_747565" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_747571" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747631" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_747634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_747635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_747636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_747637" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_747638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747631" xlink:to="loc_us-gaap_OperatingLeaseLiability_747638" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_747645" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_748057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_747645" xlink:to="loc_us-gaap_StatementTable_748057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_748062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_748061" xlink:to="loc_us-gaap_TypeOfAdoptionMember_748062" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_748064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_748064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_748065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_748064" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_748065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_748060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_748057" xlink:to="loc_us-gaap_StatementLineItems_748060" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_747651" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_747657" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_770058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_748060" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_770058" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747978" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsGrantsInPeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod_747981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsGrantsInPeriod_747981" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod" xlink:label="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_747982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod_747982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants" xlink:label="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants_747983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants_747983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_748447" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747984" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod_747986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod_747986" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod_747987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod_747987" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants_747988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants_747988" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding" xlink:label="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747978" xlink:to="loc_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding_747985" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747990" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_747993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_AwardTypeAxis_747993" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_747993" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_747995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_747994" xlink:to="loc_us-gaap_EmployeeStockOptionMember_747995" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_747991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747996" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_747998" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_747999" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_748000" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748001" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_748004" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_748006" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_748007" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_748011" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_747992" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_748012" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_747962" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_747962" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_747965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_747965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_747966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_747965" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_747966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_747967" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_747966" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_747968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747963" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_747969" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_747970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_748014" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_748015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_748014" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_748015" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_748019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_TypeOfArrangementAxis_748019" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_748019" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_748020" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_748022" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_748023" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_748029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_748028" xlink:to="loc_us-gaap_RelatedPartyDomain_748029" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_748439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_748439" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_748440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_748439" xlink:to="loc_us-gaap_EquityComponentDomain_748440" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_748016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_748015" xlink:to="loc_us-gaap_ClassOfStockLineItems_748016" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_748016" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_748045" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_768322" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_768325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_768322" xlink:to="loc_us-gaap_StatementTable_768325" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_770069" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_770071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_IPOMember_770071" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_770073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_us-gaap_OverAllotmentOptionMember_770073" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_PreFundedWarrantsMember" xlink:label="loc_bntc_PreFundedWarrantsMember_770074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_770070" xlink:to="loc_bntc_PreFundedWarrantsMember_770074" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_768328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_768325" xlink:to="loc_us-gaap_StatementLineItems_768328" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_770077" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_770079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_770079" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_CommonStockEquivalents" xlink:label="loc_bntc_CommonStockEquivalents_770080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_CommonStockEquivalents_770080" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_770081" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="bntc-20200930.xsd#bntc_GrossProceedsFromIssueOfStock" xlink:label="loc_bntc_GrossProceedsFromIssueOfStock_770082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_bntc_GrossProceedsFromIssueOfStock_770082" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_768328" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_770083" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667469069960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Benitec Biopharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001808898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3940 Trust Way Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(510)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">780-0819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BNTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,405,469<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471570712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 9,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,056<span></span>
</td>
<td class="nump">10,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,916<span></span>
</td>
<td class="nump">11,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Trade and other payables</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, less current portion</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value&#8212;10,000,000 shares authorized; 1,108,374 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">128,850<span></span>
</td>
<td class="nump">128,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(119,340)<span></span>
</td>
<td class="num">(116,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,775)<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">7,736<span></span>
</td>
<td class="nump">10,238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,916<span></span>
</td>
<td class="nump">$ 11,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667585185976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Par Value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">1,108,374<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares Outstanding</a></td>
<td class="nump">1,108,374<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667467047656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_RoyaltiesAndLicenseFees', window );">Royalties and license fees</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">1,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,690)<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (loss), net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,718)<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation gain (loss)</a></td>
<td class="nump">178<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="nump">178<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (2,540)<span></span>
</td>
<td class="num">$ (1,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (1.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">1,108,374<span></span>
</td>
<td class="nump">858,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_RoyaltiesAndLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties and license fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_RoyaltiesAndLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667469142856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2019</a></td>
<td class="nump">$ 16,594<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 127,327<span></span>
</td>
<td class="num">$ (108,870)<span></span>
</td>
<td class="num">$ (1,864)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold for cash, net of offering costs of $240</a></td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold for cash, net of offering costs of $240, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts', window );">Issuance of pre-funded warrants, net of transaction costs of $240</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss (Gain)</a></td>
<td class="num">(304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2019</a></td>
<td class="nump">16,968<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">129,091<span></span>
</td>
<td class="num">(109,956)<span></span>
</td>
<td class="num">(2,168)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,043,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Jun. 30, 2020</a></td>
<td class="nump">10,238<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">128,826<span></span>
</td>
<td class="num">(116,636)<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (In shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Forfeiture of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation loss (Gain)</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end at Sep. 30, 2020</a></td>
<td class="nump">$ 7,736<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 128,850<span></span>
</td>
<td class="num">$ (119,340)<span></span>
</td>
<td class="num">$ (1,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end (In shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance and exercise of pre-funded warrants, net of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548339656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments For Stock Issuance Costs</a></td>
<td class="nump">$ 480<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471455320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,718)<span></span>
</td>
<td class="num">$ (1,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_AmortizationOfRightOfUseAssets', window );">Amortization of right-of-use assets</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_IncreasedecreaseInAccountsAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefit</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_IncreaseDecreaseInLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,360)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(173)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided in (used in) investing activities</a></td>
<td class="num">(173)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issues of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issue transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(2,533)<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">9,801<span></span>
</td>
<td class="nump">15,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">16,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial measurement of operating lease right-of-use assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (579)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AmortizationOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AmortizationOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_IncreasedecreaseInAccountsAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accounts and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_IncreasedecreaseInAccountsAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548365624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1. Business </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Benitec Biopharma Inc. (the &#8220;Company&#8221;) is a corporation formed under the laws of Delaware, United States, on November&#160;22, 2019. Benitec Biopharma Inc. is the parent entity of a number of subsidiaries including the previous parent entity Benitec Biopharma Limited (&#8220;BBL&#8221;). BBL was incorporated under the laws of Australia in 1995 and was listed on the Australian Securities Exchange, or ASX, from 1997 until April&#160;15, 2020. On August&#160;14, 2020, BBL reorganized as a Proprietary Limited company and changed its name to Benitec Biopharma Proprietary Limited. The Company&#8217;s business focuses on the development of novel genetic medicines. Our proprietary platform, called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DNA-directed</div> RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On November&#160;27, 2019, BBL announced its intention to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domicile</div> from Australia to the United States of America. BBL implemented a Scheme of Arrangement pursuant to which Benitec Biopharma Inc, a newly incorporated company for the purpose of affecting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> acquired all BBL shares and BBL became a wholly-owned <div style="letter-spacing: 0px; top: 0px;;display:inline;">subsidiary of Benitec Biopharma Inc. BBL shareholders </div> received one Benitec Biopharma Inc. share for every 300 BBL shares. Holders of BBL&#8217;s American Depository Shares, or ADSs (each of which represented 200 ordinary shares), received two shares of the Company&#8217;s common stock for every three ADSs held. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> was completed on April&#160;15, 2020 following approval by BBL shareholders at a Scheme Meeting held on March&#160;26, 2020 and by the Supreme Court of Queensland on March&#160;30, 2020.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the U.S. Securities and Exchange Commission&#8217;s (&#8220;SEC&#8221;) Staff Accounting Bulletin Topic 4C, all issued and outstanding shares of the Company&#8217;s common stock have been retroactively adjusted in these consolidated financial statements to reflect the 300:1 ratio and share consolidation as if it occurred on July&#160;1, 2019. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">BBL announced that the transaction to redomicile from A<div style="display:inline;">u</div>stralia to the United States was fully implemented on April&#160;15, 2020. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> was approved by BBL shareholders at a Scheme Meeting held on March&#160;26, 2020 and confirmed by the Supreme Court of Queensland on March&#160;30, 2020.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The terms the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms used in refer (i), prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> to BBL, an Australian corporation, and its subsidiaries, and (ii), following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including BBL).</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Biopharma Inc.&#160;is listed on the Nasdaq Capital Market LLC (&#8220;Nasdaq&#8221;) under the symbol &#8220;BNTC&#8221;, and Benitec Biopharma Inc. is subject to the reporting requirements of the SEC and applicable corporate governance rules of Nasdaq. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BBL became a wholly owned subsidiary of Benitec Biopharma Inc. and delisted from the ASX on April&#160;15, 2020. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year end is June 30. References to a particular &#8220;fiscal year&#8221; are to our fiscal year end&#160;June&#160;30 of that calendar year. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:74%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principal&#160;place<br/> of</div></div><br/> <div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">business/country<br/> of incorporation</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal<br/> Year 2020</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal<br/> Year 2019</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">Australia</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Australia Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">Australia</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Limited</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">United<br/> Kingdom</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;<br/> &#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec LLC</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RNAi Therapeutics, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tacere Therapeutics, Inc.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667473058888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2. Basis of Presentation and Summary of Significant Accounting Policies </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation and Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;)&#160;for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of SEC Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2020.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.<br/></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment Reporting </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s functional currency and reporting currency is the United States dollar. </div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BBL&#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive income (loss).&#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss).</div><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements.</div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;1:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;2:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;3:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company&#8217;s cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of September&#160;30, 2020, and June&#160;30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;;margin-left :auto;margin-right :auto;">&#160;</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:6%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:17%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:75%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Lab equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Furniture and fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Computer hardware</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and other payables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.</div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basic and Diluted Net Income (Loss) Per Share </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2020, and 2019, there were 145,421 and 65,852 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive.</div><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 &#8211; <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(&#8220;ASC 606&#8221;) on July&#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of product occurs. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Government Research and Development Grants </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant income is generated through the Australian federal government&#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">eligible research and development expenditures. This grant is available for the Company&#8217;s research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to the Company&#8217;s activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made.</div></div></div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be claiming the Australian Government research and development grants going forward. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and Development Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Pre-clinical a</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">nd clinical</div> development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Compensation</div>. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted FASB Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07</div> and accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting for Income Taxes</div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.</div></div><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive loss.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments &#8211; Credit Losses</div> (Topic 326). This ASU represents a significant change in the accounting for credit losses model by requiring immediate recognition of management&#8217;s estimates of current expected credit losses (CECL). Under the prior model, losses were recognized only as they were incurred, which FASB has noted delayed recognition of expected losses that might not yet have met the threshold of being probable. This guidance is effective for interim and annual reporting periods beginning after December&#160;15, 2019. The Company has determined that it has met the criteria of a smaller reporting company (&#8220;SRC&#8221;) as of November&#160;15, 2019. As such, ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-10:</div> <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Financial Instruments-Credit Losses, Derivatives and Hedging, and Leases: Effective Dates</div> amended the effective date for the Company to be for reporting periods beginning after December&#160;15, 2022. The Company will adopt this ASU effective July&#160;1, 2023.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548215848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernDisclosureTextBlock', window );">Going concern</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3. Going Concern </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared in conformity with US&#160;GAAP, which contempla<div style="display:inline;">t</div>e continuation of the Company as a going concern. For the three months ended September&#160;30, 2020, and 2019, the Company incurred a net loss of $2.7&#160;million and&#160;$1.1&#160;million, and used net cash of $2.3&#160;million and $0.5&#160;million in operations, respectively. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the existing cash and cash equivalents of the Company, including the proceeds from a public offering of common stock (and common stock equivalents) that closed on October&#160;6, 2020 (see Note 1<div style="display:inline;">3</div>), management estimates that cash and cash equivalents will be sufficient to fund the Company&#8217;s operations for at least the next twelve months from the filing of this form&#160;10-Q.</div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial report does not contain any adjustments to the amounts or classifications of recorded assets or liabilities that might be necessary if the Company does not continue as a going concern. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements take no account of the consequences, if any, of the effects of unsuccessful product development or commercialization, nor of the inability of the Company to obtain adequate funding in the future. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548301160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4. Revenue </div>(US$&#8217;000) </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:73%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">Revenues from customers</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">33</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">* On July&#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#8217;s product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company&#8217;s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&#160;6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September&#160;3, 2019. The termination discharges all future performance obligations at termination date under the contract.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:60%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Licensing</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Royalties</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Development&#160;activities</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:63%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Licensing</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Royalties</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Development&#160;activities</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;33</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475764712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash equivalents<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. Cash and Cash equivalents </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash at Bank</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,450</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,231</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term Deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,570</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,450</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,801</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548412904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other assets</a></td>
<td class="text"><div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">6</div>. Other assets </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid expenses</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">564</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">861</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Security deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">14</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other deposit</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value of listed shares</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">588</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475754392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div>. Property and equipment, net </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;; width: 77%;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%;;vertical-align:bottom;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: &quot;times new roman&quot;; width: 7%;;vertical-align:bottom;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">1,283</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,344</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(841</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">503</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense was $45,000 and $51,000 for the three months ended September&#160;30, 2020 and 2019, respectively. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548405048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">8</div>. Trade and other payables </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Trade payable</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">299</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">282</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued license fees</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">171</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">54</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">43</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">155</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other payables</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">111</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">250</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;624</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;741</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548206472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">9</div>. Leases </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has entered into an operating lease for office space under an agreement that expires in 2022. The lease requires the Company to pay utilities, insurance, taxes and other operating expenses. The Company&#8217;s lease does not contain any residual value guarantees or material restrictive covenants. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2020, the Company&#8217;s operating lease has a remaining lease term of 1.7 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">September&#160;30,&#160;2020</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">156</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">218</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">375</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(16</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Present value of operating lease liabilities</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">359</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recorded lease liabilities and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease assets for the lease based on the present value of lease payments over the expected lease term, discounted using the Company&#8217;s incremental borrowing rate. Rent expense under the lease $52,000 for both the three months ended September&#160;30, 2020 and 2019, respectively, and was recorded in the general and administrative expenses.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475825288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1<div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div>. Stockholders&#8217; equity </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Warrants </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the three months ended&#160;September 30, 2020,&#160;is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:74%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:7%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Common<br/> Stock&#160;from<br/> Warrants</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price&#160;(per&#160;share)</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">145,421</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29.48</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(38,326</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">82.50</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at September&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">107,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><br/> <div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity Incentive Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Employee Share Option Plan </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> the Company assumed BBL&#8217;s obligations with respect to the settlement of options that were issued by BBL prior to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation</div> pursuant to the Benitec Officers&#8217; and Employees&#8217; Share Option Plan (the &#8220;Plan&#8221;). This includes the Company&#8217;s assumption of the Plan and all award agreements pursuant to which each of the options were granted. Each option when exercised entitles the option holder to one share in the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder or in certain other limited circumstances. Employee options vest one third on each anniversary of the applicable grant date for three years. If an employee dies, retires or otherwise leaves the Company and certain exercise conditions have been satisfied, generally, the employee has 12 months to exercise their options or the options are cancelled. After the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-domiciliation,</div> no new options have been or will be issued under the Plan. Current options on issue are under the BBL plan. From time to time, BBL issued employee&#8217;s options to acquire shares in the Company at a fixed price. Each option when exercised entitles the option holder to one share of common stock of the Company. Options are exercisable on or before an expiry date, do not carry any voting or dividend rights and are not transferable except on death of the option holder. Employee options vest one third on each anniversary for three years. If an employee leaves the Company, they have 90 days to exercise their options or the options are cancelled.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Awards </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the&#160;three months&#160;ended September&#160;30, 2020,&#160;is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:60%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Stock<br/> Options</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/> Remaining<br/> Contractual&#160;Term</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Aggregate<br/> Intrinsic&#160;Value</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,161</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.42</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.89&#160;years</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(444</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69.32</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at September&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">69,717</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.00</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.65 years</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September&#160;30, 2020</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">43,273</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">68.53</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2.26 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation Expense </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense for the three months ended: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:83%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">72</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">38</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of&#160;September 30, 2020, there was $119,000 of unrecognized share-based compensation expense related to stock options issued under the Share Plan. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548140680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1<div style="display:inline;">1</div>. Income taxes </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended September&#160;30, 2020, and 2019, the Company did not recognize a provision or benefit for income taxes as it has incurred net losses. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is&#160;more likely than not that the benefit will be realized. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475740616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1<div style="display:inline;">2</div>. Commitments and contingencies </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contract commitments </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company enters into contracts in the normal course of business with third-party contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Contingencies </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667556806552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1<div style="display:inline;">3</div>. Subsequent events </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On October&#160;6, 2020, the Company announced the closing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at a price to the public of $3.10 per share. The Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock at the <div style="letter-spacing: 0px; top: 0px;;display:inline;">offering price. The</div> total offering of 3,709,676 shares of common stock and common stock equivalents consisted of 2,666,644 firm shares of common stock, 483,870 shares of common stock purchased under the underwriter&#8217;s over-allotment options and 559,162 shares of common stock underlying <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants initially purchased for $3.09 per share and immediately exercisable at $0.01 per share. The Company received gross proceeds of approximately $11.5&#160;million and net proceeds of approximately $9.9&#160;million from the offering.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company is closely monitoring the impact of the pandemic of the novel strain of coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;COVID-19&#8221;)</div> on all aspects of its business, including how it will impact our employees, suppliers, vendors and business partners. While the Company did experience some disruption from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> including disruption of the timing and completion of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials we are unable to predict the overall impact that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> will have on our financial position and operating results due to numerous uncertainties.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667469386168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basis of Presentation and Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s consolidated financial statements contained in this Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> have been prepared in accordance with generally accepted accounting principles in the U.S. (&#8220;GAAP&#8221;)&#160;for interim financial information and with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of SEC Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended June&#160;30, 2020.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The preparation of the Company&#8217;s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company&#8217;s consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company&#8217;s future results of operations will be affected.<br/></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Reference is frequently made herein to the Financial Accounting Standards Board (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;). This is the source of authoritative US&#160;GAAP recognized by the FASB to be applied to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the Company&#8217;s accounts and the accounts of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Segment Reporting </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Foreign Currency Translation and Other Comprehensive Income (Loss) </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; font-family: 'times new roman', serif; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s functional currency and reporting currency is the United States dollar. </div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BBL&#8217;s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollar ($) and/or (USD) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders&#8217; equity as &#8220;Accumulated other comprehensive income (loss).&#8221; Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as other comprehensive income (loss).</div><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses).</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its financial assets and liabilities in accordance with US&#160;GAAP using ASC 820, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Fair Value Measurements.</div> For certain financial instruments, including cash and cash equivalents, accounts receivable, and accounts payable, the carrying amounts approximate fair value due to their short maturities. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;1:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;2:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="width:4%;">&#160;</td><td style="text-align:left;;vertical-align:top;;width:8%;">Level&#160;3:</td><td style="text-align:left;;vertical-align:top;"><div style="font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of the Company&#8217;s cash and cash equivalents, trade receivables, and trade payables are considered to be representative of their respective fair values because of the short-term nature of those instruments. As of September&#160;30, 2020, and June&#160;30, 2020, the Company had no financial assets or liabilities measured at fair value on a recurring basis. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts are reflected as a current liability on the consolidated balance sheets. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Trade and Other Receivables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and Other Receivables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As amounts become uncollectible, they will be charged to an allowance and operations in the period when a determination of collectability is made. Any estimates of potentially uncollectible customer accounts receivable will be made based on an analysis of individual customer and historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience. The Company&#8217;s analysis includes the age of the receivable account, creditworthiness of the customer and general economic conditions.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Property and Equipment </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and improvements are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation and amortization are removed from the respective accounts, and any gain or loss is included in operations. Depreciation and amortization of property and equipment is calculated using the straight-line basis over the following estimated useful lives: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="width:6%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:17%;"></td><td style="vertical-align:bottom;;width:1%;"></td><td style="width:75%;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Software</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-4</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Lab equipment</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Furniture and fixtures</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-7</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Computer hardware</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:top;">Leasehold improvements</td><td style="vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:top;">shorter of the lease term or estimated useful lives</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Impairment of Long-Lived Assets </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset&#8217;s expected future discounted cash flows or market value, if readily determinable. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_TradeAndOtherPayablesPolicyTextBlock', window );">Trade and other payables</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Trade and other payables </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These amounts represent liabilities for goods and services provided to the Company prior to the end of the period and which are unpaid. Due to their short-term nature, they are measured at amortized cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Leases </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">After lease commencement, the Company measures its leases as follows: (i)&#160;the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Basic and Diluted Net Income (Loss) Per Share </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Stock options, warrants and convertible instruments are considered potential common shares and are included in the calculation of diluted net income (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net income (loss) per share when their effect is anti-dilutive. As of September&#160;30, 2020, and 2019, there were 145,421 and 65,852 potential common shares, respectively, that were excluded from the calculation of diluted net income (loss) per share because their effect was anti-dilutive.</div><div style="font-size: 1px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company adopted ASC 606 &#8211; <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue from Contracts with Customers </div>(&#8220;ASC 606&#8221;) on July&#160;1, 2018. The adoption of ASC 606 did not have a material impact on the consolidated financial statements. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon adoption of ASC 606, the Company recognizes revenue in accordance with that core principle by applying the following steps: </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 1: Identify the contract(s) with a customer. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 2: Identify the performance obligations in the contract. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 3: Determine the transaction price. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 4: Allocate the transaction price to the performance obligations in the contract. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies judgement in determining whether contracts entered into fall within the scope of ASC 606. In doing so, management considers the commercial substance of the transaction and how risks and benefits of the contract accrue to the various parties to the contract. In determining the accounting treatment of the contract with Axovant, management assessed that the contract was within the scope of ASC 606. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management has also made the judgement that the grant of the license and transfer of associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and materials are accounted for as one performance obligation as they are not considered to be distinct; they are highly interrelated and could not provide benefits to the customer independently from each other. Judgements were made in relation to the transfer of the license and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and whether this should be recognized over time or a point in time. The point in time has been determined with regard to the point at which the transfer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> has substantially been completed and the customer has control of the asset and the ability to direct the use of and receive substantially all of the remaining benefits.</div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Licensing revenues </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Consideration can be variable and is estimated using the most likely amount method. Subsequently, the estimate is constrained until it is highly probable that a significant revenue reversal will not occur when the uncertainty is resolved. Revenue is recognized as or when the performance obligations are satisfied. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in the consolidated balance sheet. Similarly, if the Company satisfies a performance obligation before it receives the consideration, the Company recognizes either a contract asset or a receivable in its consolidated balance sheet, depending on whether something other than the passage of time is required before the consideration is due. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Royalties </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from licensees of the Company&#8217;s intellectual property reflect a right to use the intellectual property as it exists at the point in time in which the license is granted. Where consideration is based on sales of product by the licensee, revenue is recognized when the customer&#8217;s subsequent sales of product occurs. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Services revenue </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is earned (constrained by variable considerations) from the provision of research and development services to customers. Services revenue is recognized when performance obligations are either satisfied over time or at a point in time. Generally, the provision of research and development services under a contract with a customer will represent satisfaction of a performance obligation over time where the Company retains the right to payment for services performed but not yet completed.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock', window );">Government Research and Development Grants</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Government Research and Development Grants </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government grants are recognized at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognized as income over the periods necessary to match the grant costs they are compensating. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant income is generated through the Australian federal government&#8217;s Research and Development Tax Incentive program, under which the government provides a cash refund for the 43.5% of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">eligible research and development expenditures. This grant is available for the Company&#8217;s research and development activities in Australia, as well as activities in the United States to the extent such U.S.-based expenses relate to the Company&#8217;s activities in Australia, do not exceed half the expenses for the relevant activities and are approved by the Australian government. Grants are recorded when a reliable estimate can be made.</div></div></div><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will not be claiming the Australian Government research and development grants going forward. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Research and Development Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development costs are expensed when incurred. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> trials. <div style="color: rgb(0, 0, 0); font-family: 'times new roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: 0px; orphans: 2; text-align: start; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Pre-clinical a</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">nd clinical</div> development costs are a significant component of research and development expenses. Estimates have been used in determining the expense liability under certain clinical trial contracts where services have been performed but not yet invoiced. Generally, the costs, and therefore estimates, associated with clinical trial contracts are based on the number of patients, drug administration cycles, the type of treatment and the outcome being the length of time before actual amounts can be determined will vary depending on length of the patient cycles and the timing of the invoices by the clinical trial partners.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation Expense</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Equity-based Compensation Expense </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company records share-based compensation in accordance with ASC 718, <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Stock Compensation</div>. ASC 718 requires the fair value of all share-based employee compensation awarded to employees to be recorded as an expense over the shorter of the service period or the vesting period. The Company values employee and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based compensation at fair value using the Black-Scholes Option Pricing Model.</div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company adopted FASB Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-07</div> and accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is governed by Australia and United States income tax laws. The Company follows ASC 740 <div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Accounting for Income Taxes</div>, when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount more likely than not to be realized. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For uncertain tax positions that meet a &#8220;more likely than not&#8221; threshold, the Company recognizes the benefit of uncertain tax positions in the consolidated financial statements. The Company&#8217;s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the consolidated statements of operations.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Comprehensive Loss </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. The Company records unrealized foreign currency translation gain (loss) which qualifies as other comprehensive loss.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation and Use of Estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government Research and Development Grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GovernmentResearchAndDevelopmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_TradeAndOtherPayablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_TradeAndOtherPayablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548998568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlTableTextBlock', window );">Summary of entities in control</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:100%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:74%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Principal&#160;place<br/> of</div></div><br/> <div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">business/country<br/> of incorporation</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal<br/> Year 2020</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Ownership<br/> Fiscal<br/> Year 2019</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Biopharma Proprietary Limited (&#8220;BBL&#8221;)</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">Australia</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec Australia Proprietary Limited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">Australia</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec Limited</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">United<br/> Kingdom</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;<br/> &#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benitec, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Benitec LLC</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RNAi Therapeutics, Inc.</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap;;vertical-align:bottom;">%&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Tacere Therapeutics, Inc.</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">USA</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">100</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">%&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of entities in control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548354760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of revenue from customers</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="width:73%;"></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td><td style="vertical-align:bottom;;width:11%;"></td><td></td><td></td><td></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">&#160;</td><td style="vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></td><td style="vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="vertical-align:bottom;">Revenues from customers</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Licensing revenue</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty revenue</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Service revenue*</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">33</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">* On July&#160;9, 2018, the Company entered into a License and Collaboration Agreement with Axovant. The agreement granted Axovant an exclusive worldwide license to develop, manufacture, and commercialize products containing the Company&#8217;s product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301,</div> which was designed for the potential treatment of Oculopharyngeal Muscular Dystrophy. Licensing revenue consists of the Company&#8217;s intellectual property related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> and the transfer of the right to use the intellectual property of the Company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">BB-301</div> license to Axovant. Service revenue consists of payments for services provided to Axovant during the term of the license agreement signed in July 2018. On June&#160;6, 2019, we announced the termination of the agreement with Axovant. The termination of the agreement was effective as of September&#160;3, 2019. The termination discharges all future performance obligations at termination date under the contract.</div><div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of disaggregation of revenue</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:60%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Licensing</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Royalties</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Development&#160;activities</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:63%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Disaggregated revenue&#160;(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="14" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three Months Ended September&#160;30, 2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Licensing</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Royalties</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Development&#160;activities</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:right;;vertical-align:bottom;">Total</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Services transferred at a point in time</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Services transferred over time</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">4</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;33</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475739784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of cash and cash equivalent</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:7%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Cash at Bank</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,450</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">5,231</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term Deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">4,570</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">7,450</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9,801</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548174216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Summary of other assets</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:9%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Prepaid expenses</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">564</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">861</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Security deposit</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">14</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Other deposit</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">18</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market value of listed shares</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">1</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">588</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">949</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475763384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment net</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;; width: 77%;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%;;vertical-align:bottom;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: &quot;times new roman&quot;; width: 7%;;vertical-align:bottom;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;;width:;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;;width:;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;;width:;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">11</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(255, 255, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lab equipment</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">1,283</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">1,109</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer hardware</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">26</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">24</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, gross</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,344</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">1,170</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(255, 255, 255); width: 77%;;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated depreciation and amortization</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 8%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(841</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">)&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255); width: 7%;;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(255, 255, 255);;text-align:right;;vertical-align:bottom;">(796</td><td style="white-space: nowrap; background-color: rgb(255, 255, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="width: 77%; background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total property and equipment, net</div></div></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">503</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">374</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: &quot;times new roman&quot;; width: 77%; background-color: rgb(255, 255, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; width: 8%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td><td style="font-family: &quot;times new roman&quot;; width: 7%; background-color: rgb(255, 255, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="background-color: rgb(255, 255, 255);;vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667473052744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of trade and other payables</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:76%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:8%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">June&#160;30,<br/> 2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Trade payable</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">299</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">282</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued license fees</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">171</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">54</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Accrued professional fees</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">43</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">155</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other payables</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">111</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">250</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;624</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#160;741</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471352968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of maturities of the operating lease liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2020, the Company&#8217;s operating lease has a remaining lease term of 1.7 years and a discount rate of 4.67%. The maturities of the operating lease liabilities are as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:68%;"><tr style="font-size: 0px;"><td style="font-family: 'times new roman';;width:80%;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;;width:16%;"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td><td style="font-family: 'times new roman';"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(US$&#8217;000)</div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">September&#160;30,&#160;2020</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">2021</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">156</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">218</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total operating lease payments</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">375</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(16</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Present value of operating lease liabilities</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">359</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475425208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants or rights</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to warrants during for the three months ended&#160;September 30, 2020,&#160;is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:74%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:7%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Common<br/> Stock&#160;from<br/> Warrants</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price&#160;(per&#160;share)</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at July&#160;1, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">145,421</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">29.48</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(38,326</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">82.50</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding and exercisable at September&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">107,095</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">10.50</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of equity awards</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The activity related to equity awards, which comprised of stock options during the&#160;three months&#160;ended September&#160;30, 2020,&#160;is summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:92%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:60%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:4%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:5%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Stock<br/> Options</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Weighted-<br/> average<br/> Exercise<br/> Price</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average</div><br/> Remaining<br/> Contractual&#160;Term</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;">Aggregate<br/> Intrinsic&#160;Value</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at June&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">70,161</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.42</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.89&#160;years</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Exercised</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">(444</td><td style="white-space: nowrap;;vertical-align:bottom;">)&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">69.32</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;"></td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Outstanding at September&#160;30, 2020</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">69,717</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">60.00</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">2.65 years</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September&#160;30, 2020</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">43,273</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;">$</td><td style="text-align:right;;vertical-align:bottom;">68.53</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">2.26 years</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="white-space: nowrap;;vertical-align:bottom;">$</td><td style="white-space: nowrap;;text-align:right;;vertical-align:bottom;">&#8212;&#160;&#160;</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share-basedcompensation expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense for the three months ended: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><table border="0" cellpadding="0" cellspacing="0" style="font-family: 'times new roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;text-align:left;;width:76%;"><tr style="font-size: 0px;"><td style="font-family: &quot;times new roman&quot;;;width:83%;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;;vertical-align:bottom;;width:6%;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td><td style="font-family: &quot;times new roman&quot;;"></td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended</div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="white-space: nowrap; padding-bottom: 0.5pt;;vertical-align:bottom;"><div style="font-family: 'times new roman'; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(US$&#8217;000)</div></div></div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="6" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 8pt; page-break-inside: avoid;"><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2020</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td colspan="2" style="border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;;vertical-align:bottom;"><div style="font-weight:bold;display:inline;">2019</div></td><td style="padding-bottom: 0.5pt; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Research and development</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">9</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">(17</td><td style="white-space: nowrap; background-color: rgb(204, 238, 255);;vertical-align:bottom;">)&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">29</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;</td><td style="text-align:right;;vertical-align:bottom;">72</td><td style="white-space: nowrap; font-family: 'times new roman';;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr><tr style="font-family: times new roman; font-size: 10pt; page-break-inside: avoid;"><td style="background-color: rgb(204, 238, 255);;vertical-align:top;"><div style="text-indent: -1em; font-family: 'times new roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background-color: rgb(204, 238, 255);;display:inline;">Total share-based compensation expense</div></div></td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">38</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td><td style="font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;&#160;</td><td style="background-color: rgb(204, 238, 255);;vertical-align:bottom;">$</td><td style="background-color: rgb(204, 238, 255);;text-align:right;;vertical-align:bottom;">55</td><td style="white-space: nowrap; font-family: &quot;times new roman&quot;; background-color: rgb(204, 238, 255);;vertical-align:bottom;">&#160;</td></tr><tr style="font-size: 1px;"><td style="font-family: 'times new roman';;vertical-align:bottom;"></td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td><td style="font-family: 'times new roman';;vertical-align:bottom;">&#160;&#160;</td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="vertical-align:bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td><td style="font-family: 'times new roman';">&#160;</td></tr></table><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667466789816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Summary of entities in control (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember', window );">Benitec Biopharma Proprietary Limited ("BBL") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember', window );">Benitec Australia Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember', window );">Benitec Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember', window );">Benitec, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember', window );">Benitec LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember', window );">RNAi Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember', window );">Tacere Therapeutics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">X1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember', window );">Benitec Biopharma Proprietary Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlLineItems', window );"><strong>Schedule Of Entities In Control [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Principal place of business/country of incorporation</a></td>
<td class="text">C3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedBblMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecAustraliaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_RnaiTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_TacereTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bntc_BenitecBiopharmaProprietaryLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471681928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Additional information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ScheduleOfEntitiesInControlAbstract', window );"><strong>Schedule Of Entities In Control [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation Date Of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 22,  2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_CommonStockSharesRedomiciliationDescription', window );">Common Stock, Shares, Re-domiciliation Description</a></td>
<td class="text">one Benitec Biopharma Inc. share for every 300 BBL shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CommonStockSharesRedomiciliationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, shares, re-domiciliation description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CommonStockSharesRedomiciliationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ScheduleOfEntitiesInControlAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ScheduleOfEntitiesInControlAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471625800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the lease term or estimated useful lives<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bntc_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471322008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share</a></td>
<td class="nump">145,421<span></span>
</td>
<td class="nump">65,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember', window );">Grant Receivable on research and development expenditures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_FinancialAssetsAtFairValue', window );">Financial assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bntc_GrantReceivableOnResearchAndDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667475490552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going concern - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (2,718)<span></span>
</td>
<td class="num">$ (1,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in provided by operations</a></td>
<td class="num">$ (2,360)<span></span>
</td>
<td class="num">$ (545)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471608680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of revenue from customers (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues from customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667466986120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of disaggregation of revenue (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Services transferred at a point in time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Services transferred at a point in time [Member] | Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Services transferred over time [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Disaggregated revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667469069432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash equivalents - Summary of cash and cash equivalent (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromBanks', window );">Cash at Bank</a></td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 5,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TimeDepositsAtCarryingValue', window );">Term Deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total</a></td>
<td class="nump">$ 7,450<span></span>
</td>
<td class="nump">$ 9,801<span></span>
</td>
<td class="nump">$ 16,631<span></span>
</td>
<td class="nump">$ 15,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A bank's noninterest bearing demand deposits in other banks (such as correspondents).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimeDepositsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Any certificate of deposit or savings account held by a bank or other financial institution for a short-term specified period of time. Because of their short-term, time deposits are considered highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimeDepositsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667632550440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other assets - Summary of other assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_Otherdeposits', window );">Other deposit</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_MarketValueOfListedShares', window );">Market value of listed shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_MarketValueOfListedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market value of listed shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_MarketValueOfListedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_Otherdeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_Otherdeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667467087160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Summary  of property and equipment net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 1,344<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(841)<span></span>
</td>
<td class="num">(796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">1,283<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, gross</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548140120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667468988616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and other payables- Summary of trade and other payables (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payable</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_AccruedLicenceFeesCurrent', window );">Accrued license fees</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other payables</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_AccruedLicenceFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued licence fees current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_AccruedLicenceFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471695864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of maturities of the operating lease liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667472974488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease has a remaining lease term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease discount rate</a></td>
<td class="nump">4.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471528136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of warrants or rights (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period | shares</a></td>
<td class="nump">145,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod', window );">Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants', window );">Cashless exercise | shares</a></td>
<td class="num">(38,326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, ending of period | shares</a></td>
<td class="nump">107,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding | $ / shares</a></td>
<td class="nump">$ 29.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod', window );">Exercised | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants', window );">Cashless exercise | $ / shares</a></td>
<td class="nump">82.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding', window );">Exercise price of class of warrants or rights outstanding and excercisable | $ / shares</a></td>
<td class="nump">$ 10.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights excercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsExcercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_ClassOfWarrantsOrRightsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_ClassOfWarrantsOrRightsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted - average exercise price of class of warrants or exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or exercised during the period cash less exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price of class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667466982680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of equity awards (Detail) - Employee stock option - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options,Outstanding, beginning of period</a></td>
<td class="nump">70,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options, Forfeited</a></td>
<td class="num">(444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding, end of period</a></td>
<td class="nump">69,717<span></span>
</td>
<td class="nump">70,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable, end of period</a></td>
<td class="nump">43,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price, beginning of period</a></td>
<td class="nump">$ 60.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Forfeited</a></td>
<td class="nump">69.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercise price, end of period</a></td>
<td class="nump">60.00<span></span>
</td>
<td class="nump">$ 60.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average Exercise Price, Exercisable, end of period</a></td>
<td class="nump">$ 68.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Term, Outstanding</a></td>
<td class="text">2 years 10 months 20 days<span></span>
</td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Term, Exercisable</a></td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548856312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of share-based compensation expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667548454920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' equity - Additional information (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognised share based compensation expense</a></td>
<td class="nump">$ 119,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140667471282056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent events - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">3,709,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_CommonStockEquivalents', window );">common stock equivalents</a></td>
<td class="nump">2,666,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bntc_GrossProceedsFromIssueOfStock', window );">Gross proceeds from issue of stock | $</a></td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering | $</a></td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">3,225,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 3.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">483,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">559,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock issue price per share | $ / shares</a></td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_CommonStockEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_CommonStockEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bntc_GrossProceedsFromIssueOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issue of stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bntc_GrossProceedsFromIssueOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bntc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bntc_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M RE9?UFH'[38F\/YL]!PCC.W&:,IDY4!_+\50K\]5 .TWW?6_P-02P,$%
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MY0H [S>,R?>!^M[1?');_ -02P,$%     @ YC-M4?-8WDTI @  >@0  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q]E&U/VS 0Q[_**4(:2!-)T_*H
M-!(M3.,%4D7']F+:"S>Y-A:.+]@7"M\>VTFS3EIY4_OL^__NH>=D6S+/MD)D
M>*N5MM.H8FZNX]@6%=;"GE*#VMVLR=2"G6DVL6T,BC*(:A6G27(>UT+J*,_"
MV<+D&;6LI,:% =O6M3#O,U2TG4:C:'?P*#<5^X,XSQJQP27R4[,PSHH'2BEK
MU%:2!H/K:70SNIY-O']P^"EQ:_?VX"M9$3U[X[Z<1HE/"!46[ G"+:\X1Z4\
MR*7QTC.C(:07[N]W]&^A=E?+2EB<D_HE2ZZFT64$):Y%J_B1MM^QK^?,\PI2
M-OS"MO.]N(J@:"U3W8M=!K74W2K>^C[L"=+1 4':"]*0=Q<H9'DK6.29H2T8
M[^UH?A-*#6J7G-3^3UFR<;?2Z3B?D[:D9"D82UBR6US'V0*MG47%<T6J1&._
MP-U+*_D=CA?".(<*619"G< 12 T_*FJMT*7-8G8Y>7)<]/%G7?ST0/PQ/)##
M6;C3)9;_ZF-7RU!0NBMHEGX*7&)S"N/D*Z3)Z.II>0O'1R>?8,=#G\8!.SZ
M[<O_?;.R;-PH_?F$.1F8D\"<'& NQ'O7;#=?7;?AWMI6Z )A3I;_V\X.>1Z0
M_L6]YI/+)(M?]_.(]^:A1K,)4V^AH%9S-QK#Z?"P;KIY^NO>O<H'83926U"X
M=M+D].(L M-->F<P-6&Z5L1N5L.V<A\'--[!W:^)>&?X ,/G)O\ 4$L#!!0
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M/I:%M'XPM>%L*#E_/VO+$+6T!.& [JD!LD\K1 8KNM8EHCF>=0FQ0OG8RK,
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MR4Y#8D87#XL]>M&CDV?0([C1#546WC<EEG_C0U8RR$D.<A;)2<(5MN<PBMY
M$B71";[14-[(\XU.EC?WY<&/^=J2X3[X>8(Y'9A3SYS^Y\6=1+M1N[*M*' 6
M\"Q9- \8Y&-X=;<Z>_DB2^++MU$4O0:^#L)ZS0>Y._G<->B-I<%6R!+PD6?3
MHH4SN!BGO&;CF#%%9R0]<6^VVDJ".(7Q!'J]A]@$X@QNA+GGL7\0JD/0&U#2
M$I9@*\&2(.;?5TU".?8LXW623N!?-Q<>M5^-9NN'S$*ANX;Z3ARBPQS/^_;]
MD]X_ BQI*QL+"C<,C<XO+P(P_6#U#NG6-_-:$X^&-RM^B]"X!-[?:$T'QQTP
MO&[Y;U!+ P04    " #F,VU1^DJ4FL\"   -!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6RM56UOVC 0_BNG#$VMA,@K+^T "=I.V]1.J*S;AVD?
M3'*0J+&=VD[3[M?O[ !ET\J^3 J.7^YY[IZ+[Q@W4MWK'-' $R^%GGBY,=6Y
M[^LT1\YT3U8HZ&0M%6>&EFKCZTHARQR(EWX4! .?LT)XT[';6ZCI6-:F+ 0N
M%.B:<Z:>YUC*9N*%WF[CMMCDQF[XTW'%-KA$<U<M%*W\/4M6<!2ZD (4KB?>
M+#R?)];>&7PML-$'<[!*5E+>V\7';.(%-B L,366@='K$2^P+"T1A?&PY?3V
M+BWP<+YC?^^TDY85TW@ARV]%9O*)-_(@PS6K2W,KFP^XU=.W?*DLM1NA:6V3
M@0=IK8WD6S!%P O1OMG3-@\'@%'P"B#: B(7=^O(17G)#)N.E6Q 66MBLQ,G
MU:$IN$+8C[(TBDX+PIGI0M'W5>89F,@ '^JBHHR;+@@T8]^0 VOFIUNR>4L6
MO4(6PXT4)M=P)3+,?L?[%-@^NF@7W3PZ2KC$J@=QT(4HB((C?/%>;>SXXG^H
M[<*B9,(XT5<OHC]3$7R?K;11=%E^'/&7[/TESE_R?[)[E,R6Y[FN6(H3C^I/
MHWI$;SJ$D[MEY^V;410.WP5!< J4,X-\A<HE[E,MT$V6<FT:IA Z$(;M<,U6
M+T%!V(U&,8UA< 87DE>U(8J<J<RAHH%]KI$*()=E!@6OE'Q$B]00)?;Y(@TK
MH7I%\D9)K8D^3A+K9!C +$UK7I?,8$9U1)+2@K652DC&I3+%SW;C9)2$< HG
MP[,!O8[[H=22NGX0TQ@/$[@\9,8G:F8:H6$:.DF_2PES^$X_='-J<F!RI)]"
M!-Y>9K27^8^TVOOHD%$0GG6I.^D*77\IGWOPMXOC'Y0H1[5QC4A#*FMAVFK=
M[^Y[W:PM\1?SME'>,+4IA(82UP0->L.^!ZIM/NW"R,H5_$H::A]NFE._1F4-
MZ'PMI=DMK(/]/\#T%U!+ P04    " #F,VU1@?#NX%D"   /!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6RM5%%OTS 0_BLG4R&04),XZ=J5-E([
M0( T4:T;/" >W.321'/L8#OK]N^QG31T$NL3+\Z=???=]UU\7ARDNM<EHH''
MF@N])*4QS3P(=%9BS?18-BCL22%5S8QUU3[0C4*6^Z2:!S0,+X*:58*D"[^W
M4>E"MH97 C<*=%O73#VMD<O#DD3DN'%3[4OC-H)TT; ];M'<-1MEO6! R:L:
MA:ZD (7%DJRB^3IQ\3[@>X4'?6*#4[*3\MXY7_(E"1TAY)@9A\#LYP&OD','
M9&G\[C')4-(EGMI']$]>N]6R8QJO)/]1Y:9<DAF!' O6<G,C#Y^QUS-Q>)GD
MVJ]PZ&+CF$#6:B/K/MDRJ"O1?=ECWX>3A%GX0@+M$ZCGW17R+#\PP]*%D@=0
M+MJB.<-+]=F67"7<3]D:94\KFV?26\5R!"9RD*9$!0U[8CN.>A$8B^YB@JQ'
M6G=(] 6D&*ZE,*6&CR+'_'E^8%D-U.B1VIJ>!=QB,X8X? <TI.$9O'B0&GN\
M^ 6\32_-JUUEF6H9U_!SM=-&V<OQZTR)9"B1^!+)?^CF620WBW/=L R7Q Z;
M1O6 ))W!F[OMZ/6K&8VF[\,P? NV1P;KG2WE&O6U%>B-CD=?'49 +R_=.J.=
M;LR!5YF=+(0";4.B:0239#AKE"Q0N[%CO M(8H@F$_CV3!1$401T$L*M-#9P
M!!<TL>LTB>!?K0Q.+FF-:N]'44,F6V&Z^SKL#M.^ZB[YW_#NJ;AF:E\)#1P+
MFQJ.IQ,"JAN_SC&R\5=^)XT=(&^6]L5"Y0+L>2&E.3JNP/ &IG\ 4$L#!!0
M   ( .8S;5&'^!HY+ ,  /P&   9    >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;)55;4_;,!#^*Z>,32!!\]*6,M96 K9IDT!"O&P?IGUPDTMCD=C!OE#X
M]SL[:2@(*NU+$MOWO-S9ODQ7VMS9 I'@L2J5G04%47T<AC8ML!)VH&M4O))K
M4PGBH5F&MC8H,@^JRC")HL.P$E(%\ZF?NS3SJ6ZHE HO#=BFJH1Y.L52KV9!
M'*PGKN2R(#<1SJ>U6.(UTFU]:7@4]BR9K%!9J148S&?!27Q\.G+Q/N"7Q)7=
M^ :7R4+K.S?XF<V"R!G"$E-R#()?#WB&9>F(V,9]QQGTD@ZX^;UF_^YSYUP6
MPN*9+G_+C(I9<!1 AKEH2KK2JQ_8Y3-V?*DNK7_"JHV-.3AM+.FJ [.#2JKV
M+1Z[.FP CJ)W $D'2+SO5LB[_"I(S*=&K\"X:&9S'SY5CV9S4KE-N2;#JY)Q
M-#]'3LE.0V(N-Q.F'>ZTQ27OX(9PH145%KZI#+.7^) ]]$:2M9'39"OA-=8#
M&$;[D$1)M(5OV"<V]'S#K8G!GY.%)<-[_W<+YZCG''G.T7\7:SON,]P4"&>Z
MJH5Z@D)80$5H, .I2(-0P)?,"))J":73 +YMH/-<I@BV%OQLN,S&18JE0>1;
M04"%(,#'6AK.4RI7N&3@E5H.@_>-7Z,-<9:KQ1,T)$M)$NT^(VUCA$IQ'T@\
M<KA0&6C&F U7+,,7$>U@,Y-/'XZ2>/+%=GJ99K#2!"F?#&X'X/187V:-*.%!
ME W"LA&L1<B1G"%?*C22%SF*C/07E-$/J#B&M4XX*@<^&835@OVLC\?^9DJ]
MB]<U='463.U:T_,L*U:.-1Y,X F%:?,5D$F;ZH;+RASH D:#P\G'-E_VV1A?
M+K?@M%]KE5(LNHJ", @LG>N2.YX]AMW;ZYW.9!1%>V_DXQXQ[$ \/O2["$E\
M!#>:N#*OA7CSW.9;&$[&<(Z6=[ZJ&VJ/$KHZPFY\"'MPR=_NE+1U9]O;+._
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MEP(4KF?>(CP[3ZR\$_B;XU;OC<%ZLI+RSDX^9C,OL(2PP-18!$:?>[S HK!
M1.-;B^EU)JWB_GB'_M[Y3KZLF,8+6=SRS.0S;^Q!AFM6%^9:;O_"UI^!Q4ME
MH=T_;!O9B"RFM3:R;)5I7G+1?-E#&X<]A7'PBD+4*D2.=V/(L?R3&3:?*KD%
M9:4)S0Z<JTZ;R'%AD[(TBG8YZ9GYTLCT+I=%ADK_ ?BMYN9QVC>$;/?[:8MR
MWJ!$KZ#$\%D*DVNX%!EF3_7[Q*BC%>UHG4=O BZQZD$<^! %4? &7MRY&3N\
M^!6\2^<8_+-8::.H$OY] S/I,!.'F?QBZ-Y$L4UWIBN6XLRCKM*H[M&;AQ#
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M\V/1W+H_Q)NWRV>F-IPX%+@FU: W&GB@FO= ,S&R<G?P2AJZT=TPIR<4*BM
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M;^L000]MQM!FX"81Z@+=V*D+$*;BW?3#103=6MT)LX=*5F LL7I*VQCY"T%
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MSL IWW.ZR(\"WF([AB(;09[EV1&\8M!81+SBWQK?18WP_7SEO.4;\>,(_'2
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MVP"TM*43KPW^B%-ZDFB?7[SXX?KV-;^<O7@TO.;&E,Q7)N(T++N^O8FKZ R
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M^%E#=O"4HTS+D5#X#G$5@LM'WA<%+>R>#UH5T(*F+]NFM>E!(%](MQ9+'#I
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M)S[GB&\:L^4?JEF8!AD/OUPK.'=+#^#[I3%-?$,;I)\N^OY_ %!+ P04
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MST#M',B^5LIN-RY ]Q>:_@%02P,$%     @ YC-M4='I;Z5R P  !@D  !D
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MJ9V?DFA6_EE"$QS\_4IKM]N$ -U#E_\%4$L#!!0    ( .8S;5%C+$^)8 (
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M:S0/S4I9+1A8\JI&H2LI0&$Q)XOH>IDX>V_PL\*=/I#!9;*1\M$IW_(Y"5U
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M%TO[AZ%R!O:^D-+L%>=@^!73?U!+ P04    " #F,VU1H[2'EZ8"  #=!0
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MDY'16S ^F]#\(E@-U22.*_]1%L[0*:<Z-[E&LF3A_(XM!=J+4>P(U!_%JSW
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M[GZ$UWZ8^*CE))I-&"P6PE75W=?L-K-K6K?L<WH]^&Z8V7!EB7Y-I4FKWXW
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MJX6RL[A#R2D'H:D42$$QC2[3MW-\X0R:'5\H;/3.&+E45E+^<)./^31*7$3
M(#,.@MB_.[@"QAR2C>/G%C3J?#K#W?$C^OLF>9O,BFBXDNPKS4TYC<XCE$-!
M:F8^R<T'V"8T<GB99+KY19OMWB1"6:V-Y%MC&P&GHOTG]]M"[!B,\!,&>&N
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MIV?8*U3]?*@'1I;N0EU)@]>S^\SQR07*&N!Z)J5Y'-@ [2-N_!=02P,$%
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ME,%@BL)4,S@:P\C2]=Y&&NQDM\UQUH*R#GB_E=(<#/M -[V3/U!+ P04
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M)+AT0=R.#<YRG"8U*4T.U[M<94WX#D3SS2_=#[=D?[B!_U7$G',$7%H@KO?
MAM70!^,-;P=<VB5NR2]SG#-OQ)>KEWZ(ZPVQN?@WO"IP:9:X';><Y3C]NIUW
MC_J^!$1HVV&)UGS+5-8O%;-%RWUK&\U7\U/3BMM^LH3)^O@[(D+*)(IAHR&]
MJX$^BB)KC;.!XJGM+E=<Z5[57D;Z<P*$"=#W-YRKP\ L4'R@3/X"4$L#!!0
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M>BQ#UW-0F- ;+7]=SM'UU0VZ0H2AEXR74@-R["IMTR1ST]K2M+(4?&)I"<4
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M;YLP$,>_BH7ZT$I;(9"0M")(;:IIFU0M:MKM8=J#$R[!JL',/I+TV\\V%-%
MT%[ QO?_^W=G.**#D*\J!4!RS'BNYDZ*6-RZKMJDD%%U+0K(]<I6R(RBGLJ=
MJPH)-+&BC+N^YX5N1EGNQ)%]MI1Q)$KD+(>E)*K,,BK?[H&+P]P9.>\/GM@N
M1?/ C:."[F %^%(LI9ZYC4O",L@5$SF1L)T[=Z/;Q=3$VX"?# ZJ-28FD[40
MKV;R+9D[G@$"#ALT#E3?]K  SHV1QOA;>SK-ED;8'K^[?[&YZUS65,%"\%\L
MP73NS!R2P):6')_$X2O4^4R,WT9P9:_D4,5. X=L2H4BJ\6:(&-Y=:?'N@XM
MP6A\1N#7 O]_!4$M"&RB%9E-ZX$BC2,I#D2::.UF!K8V5JVS8;DYQ15*O<JT
M#N,?F((D5"E 13Z357681&R):*]</@!2QJ]TR,OJ@5Q>7)$+PG+RG(I2T3Q1
MD8N:QGBZFWKG^VIG_\S.*RBN2>!](K[G>SWRQ;#\>YF?D[NZ!DTA_*80OO4+
M!@MQ5Z7[^VZM4.I7[,^ <] X!]9Y?,9Y*:&@+"%PU)^>@MY250ZA=3 ?WCZ>
MA./(W;?KT8V9A:,FY@/:N$$;#Z*M8%-*AF_ZQ2^$8MB'5CE,6MN.3LFZ(>%-
M/]BD 9L,@E6G,4 UZ6QY<P+5C1C-^J'"!BH<A'JD\E7WU3WE)9@OA#.%D!"5
M4ME_JF$7X01R*.(#X[1AG XR/@NDO(]EVGW#9K,3FF[,S?CT(-U6KS%]7A=E
MQW)%.&RURKN>ZF1DU3NK"8K"MI^U0-W,[##5OQN0)D"O;X7 ]XGI:,T/+/X'
M4$L#!!0    ( .8S;5%85-1()0,  /T+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;+U646_:,!#^*U;4AU:B39P @0J06KIIG5H)E79[J/9@$D.L
M.G%J.]#NU\]VTA @9&@3?0';N>_\W7>7RPU6C+^("&,)WF*:B*$529E>VK8(
M(APC<<%2G*@G<\9C)-66+VR1<HQ" XJI[3I.UXX12:S1P)Q-^&C ,DE)@B<<
MB"R.$7^_QI2MAA:T/@X>R"*2^L >#5*TP%,LG]()5SN[]!*2&">"L 1P/!]:
M5_!R#'T-,!8_"%Z)RAKH4&:,O>C-;3BT',T(4QQ([0*IOR4>8TJU)\7CM7!J
ME7=J8'7]X?VK"5X%,T,"CQG]24(9#:V>!4(\1QF5#VSU#1<!=;2_@%%A?L&J
ML'4L$&1"LK@ *P8Q2?)_]%8(40' ]AZ 6P#<0P%> ?!,H#DS$]8-DF@TX&P%
MN+96WO3":&/0*AJ2Z#1.)5=/B<+)T82KBN#R': D!/@U(ZG*D6R!1%70.9CF
MR06 S4%::VD,3V^P1(2>*<33] :<GIR!$T 2\!BQ3"AS,;"EXJIOM(."UW7.
MR]W#:XK3"^ Y+> ZKE,#'S?#OV?)/KBM%"IE<DN97.//^XM,+3"A2$6M-?A2
M:O!\I\S!K<2Q^-5PF5=>YIG+VGLN>V02T3UZM\"",U$K:.ZT:YSJMW<Y@EZ[
M/;"75=EJC*#OE$8;?-LEWW8CWZL@R.*,(HE#]0:I;A(0E+^CBCF*&9?DMSFH
M8YV[[E0(G??:<(MUC9'?[]:S[I2L._^ALBKK.K:='2(=Q]LBNVOC^>UZKMV2
M:[>1ZY3-Y0IQ#)[O<3S#O*G*_-*G?_R2[I67]8Y1TKT=*>%V:32:;'#MEUS[
MC5SOT*S2WPY0'#KK9NL<7W-8Z>WP&*H77C<T=7O;95YG!9U^O?9PW6BAV\AY
MS.(TDYB#"/'PT)J'Z]8*O4_(P+HSPN;6^*\9V&UX;G=;_T:;3;[KG@B;F^(=
M5B-1Q&@(2*Q8+[$F*@Y*P;J7P>XGI&#=YJ!_E!3X.U]*=_MCVFR3\[4KLYD>
MC.\17Y!$ (KG"N1<^"HA/)\U\XUDJ1G79DRJX<\L(S6?8ZX-U/,Y8_)CHR?
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M277BF6&A_DG(M4"]SQF3NXD^]H:_7/(?4$L#!!0    ( .8S;5$#^6K*5P(
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M)CJ$HJKPU4#QW%;5-5>Z1MMNJE]%(,P"_7_#N=H-#$'SSEK\ 5!+ P04
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M'N\"CP^?6"X3 7=YC'&'_:K?WO5Z!&R5G"9#WBE#2Z]7<8/%$'SG!CS'<[J
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M:$* OZ^)W-D)4S+L>/$'4$L#!!0    ( .8S;5'M= Q 6 ,  %4*   9
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M==?KWBR$[]7;W\WTPJ4MV+^YD[]02P,$%     @ YC-M49>*NQS     $P(
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ YC-M44X,JK3U!   F10  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .8S;5&F)'HF#04  /\2   8
M              " @3<-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #F,VU1JM"Z@VD"  "-!@  &               @(%Z$@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ YC-M426V?P2N!
MZQ$  !@              ("!&14  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( .8S;5&:'B"OS@0  'X3   8              " @?T9
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #F,VU1\UC>
M32D"  !Z!   &               @($!'P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ YC-M45FR;,>R!0  LQ4  !@
M ("!8"$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .8S
M;5'E=<N8V@4  $P.   8              " @4@G  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #F,VU1(*V-S785   G/P  &
M        @(%8+0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ YC-M4=-Y,7Y= P  .P<  !D              ("!!$,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #F,VU1A@FB=DT#  ! "
M&0              @(&81@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( .8S;5%EO[#E0P(  /X$   9              " @1Q*  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ YC-M4:_?"9)1
M @  Z00  !D              ("!EDP  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #F,VU1^DJ4FL\"   -!@  &0
M@($>3P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .8S
M;5&!\.[@60(   \%   9              " @212  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ YC-M48?X&CDL P  _ 8  !D
M         ("!M%0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #F,VU1]^W(4@<$  "@"0  &0              @($76   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .8S;5&LI!+<K@(  +T%
M   9              " @55<  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ YC-M41=+DM(I P  %@<  !D              ("!.E\
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #F,VU1L=1\
M)_<"  !Y!@  &0              @(&:8@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( .8S;5'ADS&N;18  ,9(   9
M  " @<AE  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MYC-M49+[12G? @  D08  !D              ("!;'P  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #F,VU1T>EOI7(#   &"0  &0
M            @(&"?P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( .8S;5&>EYC[3@(  /0$   9              " @2N#  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ YC-M46,L3XE@ @
M^P0  !D              ("!L(4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #F,VU1A3:QLZ<"  "K!0  &0              @(%'
MB   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .8S;5%Q
M7S*[90(  "$%   9              " @26+  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ YC-M4:.TAY>F @  W04  !D
M     ("!P8T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .8S;5'I'?<Y2@,  - )   9              "
M@3Z?  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ YC-M
M4=BLZ(EK @  R04  !D              ("!OZ(  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #F,VU1H,-0B[X"  !R"0  &0
M        @(%AI0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( .8S;5$?=U_$*@,  *P,   9              " @5:H  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ YC-M44K=^G%E @  X@8
M !D              ("!MZL  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #F,VU1Q/37^GD"  #,!@  &0              @(%3K@
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .8S;5%85-1(
M)0,  /T+   9              " @0.Q  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ YC-M4:*Z[\Y! @  (P4  !D
M ("!7[0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #F
M,VU1RO9F(WT"  #Q!@  &0              @('7M@  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .8S;5$#^6K*5P(  -L%   9
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M970T-BYX;6Q02P$"% ,4    " #F,VU1D2,%-_T!  #O P  &0
M    @(&UR   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M .8S;5'M= Q 6 ,  %4*   9              " @>G*  !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ YC-M45JNZ@E% @  @ L   T
M             ( !>,X  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #F,VU1
MEXJ[',     3 @  "P              @ 'HT   7W)E;',O+G)E;'-02P$"
M% ,4    " #F,VU1]BO#\0P$  #7'P  #P              @ '1T0  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ YC-M49(LH):X 0  YQP  !H
M         ( !"M8  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ YC-M48Q/ZH^Z 0  [AP  !,              ( !^M<  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _#P  Y=D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>98</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>35</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcern</Role>
      <ShortName>Going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Cash and Cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Other assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssets</Role>
      <ShortName>Other assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/IncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessTables</Role>
      <ShortName>Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Business</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Revenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Cash and Cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Other assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssetsTables</Role>
      <ShortName>Other assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/OtherAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Trade and other payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>Trade and other payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.benitecbiopharmainc.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Business - Summary of entities in control (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessSummaryOfEntitiesInControlDetail</Role>
      <ShortName>Business - Summary of entities in control (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Business - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BusinessAdditionalInformationDetail</Role>
      <ShortName>Business - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of property and equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Going concern - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/GoingConcernAdditionalInformationDetail</Role>
      <ShortName>Going concern - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Revenue - Summary of revenue from customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfRevenueFromCustomersDetail</Role>
      <ShortName>Revenue - Summary of revenue from customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Revenue - Summary of disaggregation of revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/RevenueSummaryOfDisaggregationOfRevenueDetail</Role>
      <ShortName>Revenue - Summary of disaggregation of revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/CashAndCashEquivalentsSummaryOfCashAndCashEquivalentDetail</Role>
      <ShortName>Cash and Cash equivalents - Summary of cash and cash equivalent (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Other assets - Summary of other assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/OtherAssetsSummaryOfOtherAssetsDetail</Role>
      <ShortName>Other assets - Summary of other assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Property and equipment, net - Summary  of property and equipment net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetail</Role>
      <ShortName>Property and equipment, net - Summary  of property and equipment net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Property and equipment, net - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and equipment, net - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Trade and other payables- Summary of trade and other payables (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/TradeAndOtherPayablesSummaryOfTradeAndOtherPayablesDetail</Role>
      <ShortName>Trade and other payables- Summary of trade and other payables (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Leases - Summary of maturities of the operating lease liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesSummaryOfMaturitiesOfTheOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of maturities of the operating lease liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Leases - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Stockholders' equity - Schedule of warrants or rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfWarrantsOrRightsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of warrants or rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Stockholders' equity - Schedule of equity awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityScheduleOfEquityAwardsDetail</Role>
      <ShortName>Stockholders' equity - Schedule of equity awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Stockholders' equity - Summary of share-based compensation expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquitySummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders' equity - Summary of share-based compensation expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Stockholders' equity - Additional information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' equity - Additional information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bntc-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Subsequent events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.benitecbiopharmainc.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bntc-20200930.xml</File>
    <File>bntc-20200930.xsd</File>
    <File>bntc-20200930_cal.xml</File>
    <File>bntc-20200930_def.xml</File>
    <File>bntc-20200930_lab.xml</File>
    <File>bntc-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001193125-20-292209-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-292209-xbrl.zip
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M4J'FQ-1E8$KKM.R.GL6$;7=0#*8/'/:W9LANF?#9Y+)MIJ5?3FWA&O^6WV>
MFM9C&Z.OVTN'C=:"4P'X:76V,:9[ZD;@R[+F^)<WXU0@*HL_TOIK<Z3[S%$
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MJB?62 E2%)LZPA F*(IR%(0C3! +-YQPA EBX883CC!1=30[M\E>W#9O%XT
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MB/+@O1,^JZ2PGVDZ;; 5KZ[..RTUD:&KP-C:1'EF#BS( 7D#.!C;0D(XLUU
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M('7])&=XRHREXTH.FJ()@(QB<8T[#L.F8$GMD( %5 C/U!=$RC0I8UK?93\
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MZ038'M(Q@;EGGM FV,6L.^R<#0<MA2TR/58M-YAV>Q-W@6B)#;G8.&/!VRY
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MYV)*S%1O9KI\?!3\D;D),? 9B(EJ6HO6]#=F>K60#)0;0+D!B])!*Q:;HC2
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M5)FAAW_:B>';B)=+D> 4\-2X6K9@1VZK2ZBF[= U;4E"-K>J:2U#-K7&+8]
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MRDW\$#]EY"\S>5/M,W.4G[J]LU:K)1W'GWJJ_#RVA>)../R_X%R9PO031^&
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MVH7RVIUP)0RWMUOOK^WIC%GSQ3?J^S>*X2@,>$/,;"&Y"* 04ZXK8'IQH>
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M%,D$2+2 5TSED5L<%)D"O&9H^!HLTA- UFA"V(XN<N.9 OK.!%A3VRO3U]A
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M4'#XD!UU P7+GIAA2G,3+48>V>>!!M4F!A_'O"0=?"D'?C]']Q:C>J&5&?Z
M_O C\RU%,)9\W8W&OA9%K=#4=!P95N1"@@.;V'<@ QFB/!G\V9$"(F9FX;N^
MD^W_%/9\13  +S$P R22"#BL"/@4^&_7H?]V'_/?D)HWTCE H@L^ 9<"[;K/
MX(1.N?+ZB^TX;QHM,^(#K:;\&7"L,,8;*^ILC\6/1\*F7_C/?E CE,>+KP-+
M.^O:C.4MM.\JU*@-9.ZR O@7/8&L 'CE]>7O'\"= #Y,A(U#!,P\,;.=T*=>
M?GW"'-^J".,.,I  +D06II37/[U!!+^%R5[_?O?A#8KL*+071SC8-CG>-LC\
MV%S,#7S<6$@#A1V7?F;X<V %*<Z$<U?&,"Y Z3YQRUN*%V8.'T9.Y.C2NP^F
M@TV)ZD&*=T]&])/+P?"&#7;61S\<E#3/EJ;B#%13+#R2#KQ$<9F+I)R(3A%@
M5$/JC3 D@/$^!#GT]=UT^$<^Z,.)KE_P2:K6,*@.5&*1:I4!(M?6?H!=JG/A
MQ'@O#'O!"W'?5=.\J>>OTH]U: EQ9@3BS$1Q=A%S<Y5?F1$H-?Q-GN!@<&&Q
MONSH5QS!Z8.!Y&TY*<VY BQ<4@'8UPB"8*/CEM[9!36G<B72>L4HC\[ 0_)9
MVDE<@"2Y J.;YGQU#/51LN!KG_^6*4S6TEZM)3P&_1L&9)7?.,/3''\K-]D$
MVD.0(G09IC[.?-<@TO;Y1V#I#(BE@*(G=<WEW;4R;+?.,F^[V!W9D]D :,&$
M)QUQ9VYQ]'(6;'MI9C!GXHM\_(!:"_PZ_Z%%^"4ZW#E;G.C)'V9L[G^;."<(
M3R79;";L%QD_]X_MY0%">!8#K\!7S@2/H.$1L!EDS+.H%W;4$CW.JF,;3[^<
M>(+-HV?HBW.X==Q[$3(EGIRA"QRCQ1EH OO)0/F?&-/?'M*XB.CF^P/!^77(
M7[&DDB 2[P0A?+!T$3/RK$>^I.!J$%.Q,:<Q)CX#'UW:=*C-_!"\3.E!Q>4;
M'(D<(]N"SUH@]N394C@/+  4W=1P\V8*(%TL&1?A2:LJBFFX7)M8QA\>&OR.
M!]9H8* #E_P RUGR-AJIKV7 4<BP2/#;#&Q6T)!G08*25,31\X'N#< "TRLX
M+0H>Q+V+.W$,1']SM@B%:GA8'I_4D8D#8%_C;3R^0<?%$TP,KR.GN?,@[B.Y
M H<-GI5Q-GS_#>VU<*\M.,%S8=?\&[V?..],##".A3:9^WP&],63)?F<3^*9
MYTI6S6(?=#ND/Q%P8'Q@Z1^Z$\'!,0/*PKX%5\P,\B/\C8_,CK$W> "C:WIT
M ZF?E@ N:3""_^XF-T[VTT3:\,+)_DG>-YE,8%?\#/8U%TR6*=;S1UK<&UFJ
MP-&_[#*CD"^ ;QB,^@5Y)QI:?;?5X)5LY4(E@74J(+]Y0 DLF320"*'>P$(3
MD &^7E!>>Y8?IN#Z&]^TE$?4OO+PLS'\4+X6Z73X+J'25YKV!>HR8JC13,[$
M.^!L=X(X?EF@,W'S:8X0H9?IY>U>CI4EX0Z.N\T-@(64*"G1/"7:)B5:GHL_
M2\UY%L\(36K/11:AO5"W9PHWY.,Z>'\:IJK)&I+PKS!',TP_28Z'ZM8Q8$U,
M9"O;#!6-3MGR*)'2+C)D.%8B*]*?A]0[O7PL+Y-Z)_5^G.J]0^J]/!?_;ME+
M7C(H0S\5#92C:\H(J&6'L52=N4SA+X83Y-L+CF>4BHZTL&>@@/USE_SZB^C)
MASD\?!;,!>-@[<HB@(9*>!&_9<*O_+-<Y5D6[WD.*65Z^6A>;K92/OK3B*6#
MU%4EI_G'MZ[ @IU$89X\39)?!R>W?FI0K-PZK"R+*JS]HFC_M!:^G''?%XI.
M,3#M36-!<I4\B,(SW7-8^52QF!L4FOJ"-G8(C7EMLF0>^P=,'[A8+@#V <XN
M#DY47RD3IJ/26#H+3?E=P1&,3#&+'<-@XEBL%%U6Q5$Z\&$37*Y#QI8?/D:,
M32DN^?2[SI,&B^"'_$$V34 [R9([X8%9/_"4.]JV.I_9CJRXP5P79L$^,F"-
ML*^"3(VYOZ7QV'$*<$_\G8;I]?*-9-:)X7K2%CL+ZG"L'PJ6ONF"C5$,7"6_
MD!(I,,\6&9=!W6Q4<6U;P;%XK.@HD=M*&_C0&]@&6EANF%4*_/+-<'[0[LTG
MWJ>L7*T@Y<#&RF6_X-GQ'O[%@TX0H?X#M1WOI*#%<2_;/(#2,UQ%( 6"1BP8
MNISZ_4_P 9 +R:J:*3-D=R(GD@:H-;D>=/Z!7Z0JS=[K,O/\!5NLR!27I;>P
M\LYU_O_VOK2W;31;\WL#\Q]X@VG  23%:Y)RN@MPG*0F=U)5N7%\[WPKT")E
ML4.1:BZV5;]^SOHN%&DI3F1;*38:E42B^.[G/<MSGN.WB AZ](+:7/B(,$."
M>(8W<D!5T&<#)\>'0"V2'B]3YDY/8EZ<"QC#FRUG<BPXS1D8#=\A@I )R8O%
MTIC9NF1EQ\Y;@8G3:70GS.S=Z&I]S\!-RSZ'3>@0Z@;'85WE^@FQ0LA'*[Q/
MWTF0/C8]_!$)TL^DL-L,J$]6H]\::0JJOAHS8"P@SLW0AR0*(%T8:H3Q%%[#
MYS1TV3]P#IQ$!4EDD#R-ZVF,:GP4HP:#6;TJ^I2EA!6'I"0B [ ^0"YX=#"N
MC/5Z!^I'"<.Q $07$6LZ3?0(AND#^PWZTD+8[C :=95$-24BZ<M@-$Z*2V-I
MOA?3P'6![\DG$W<;."+6$\%^.K;VW^0(4 +0I;'SG$F0B1F(++T&37+*Z9;R
MK#=JH8\+8"=D^2P9XY44D83M.0\>@O, SY2P&*&A-:?;=%M$RP,LGC=CL9DQ
MO.8IJXJL*H38#J!IRA(+G<0OEV6*3; 9YLC]21^,@K>8@ >G@=(3F)H'B0TR
M(P&1BRPI6*N0;#TRD^"8HID4O0HPWB,6%YA-\768BK*4S!#O'=N<\7$XIYWQ
M)U(@_,^4:!\[QU;$%7$&*F'3->:2X_R04I5/E&V(A\F(9<X66&_LTL@L1XHC
MD[7G^)Q\S0\5.\Q)(M,S+XD#QDURLS?%*'AS:[LH_-N'G:"'+1U+[SG6P,ES
M14C,6;@IA$8)35A6' UP5^^7R.,:NPM$UU.0OB7^R"_ZRP4@1;,-Z%\!*;:O
MEL)TM\<CG2YX7N]F%/*Y\^O6\& [Q;:VONK7\MB+^VCEQ5'[<X^FDE5;N8#[
M^-O73?JZ0>FN89[ED^H:A.,W-GOW#FQ(-ST8'GI:*3*"EH]UJ]WODG\(+^PU
M]..M^XM^W=N;>U<7&>E^S&F9W) >V&^ O\P&0$N\AOD,IF$1_9A"_ZA?^PZA
MC[3"R"7B&6H/M@$H( @[45PX3'I,\4&D_VHU;;K7L<=";?^/>P?<1AQP[V?H
MT)D)H="'/+L<?DC0!R+$3[TG[BZ>N")&7D A&$_L%&.<($97#;)>,42(6: H
MH.#19VMAB-A&%!O8+"_''OFI,<QXP0S8R)0%(@_YM>0? EV8!"FN<4IK+$ E
MQEUAD)"&0CGCB0-8NE@(\12R6ME(Y&W=D3"F(Z@S)#K YW!6F'7 < V4Y$LD
MR 7WA9WTE25(IK>.@O>K6\; ;QPQN<JZS:-/SUTFC@'A'"Q3-4N3\"\-M[;V
MQW3:=(B\<P[NRWFF' 7OG,3\TJEQHR$ESP-(/_+B)6;^9&S.:)U9)H<NP8R%
M@2.9&#)T$[NB;?,U3L)>*&\NZLJI: 8PV4OCV\"K96P"O09$ZD$P41I?YDA"
MAG,KG"6E\M!$*K44N4%<&T:4X6I,W* OU8(B&8 BO\Y ?$2CX,T2PY"+1I5@
M,_'_.WA0B0AXD0M)R[,GF:.EAN"(VBP1.!I'YA=U69/8P+X0' ZNE8/=( H7
M)9<7(G%&P9[^B#_D$2=S:WL.]$DE)ABH ;-8J(]\&#07WD#$9+-"C0$F5%S.
MR*<@XJ=!Q D?I$:RS)5F;3\?LF6"8^5:+[;7IQXIH2F=S;%08Z60#OK9 ,X6
M04J9W F?&X>94;#\*],4),/(*_W8G9>Z%*JW)!LS!U288IBHX# =OEL3@X0>
M5OE-B5,^1K*E)J:,,X.(3![)0D,"X?$[&5!. :D*=0C672A(B#H2*RB@K2*Q
M:>[8UG=8 +OB\">&2A%)(?3I&W#>;.BU:U4AXBE@A<[;SHV]/@B47D6JVBWD
MB81 D53MB:$K*K01(8@2F0K!8-(X70$E2W"S0F6)Q&+N?;1\')E1]YZDQ>V@
MN9,)^FY620R/"#%E@1B62CIW'.PD3FW&ELE>(5@X@(\(!ELV:Z4T</3ML$WF
M<>'%G:39M;_2GD<I)KK+ZNU?9U:YZ3P*@Z5'6\^$(:1C3 ?",FSQ)%,[2>B5
M"9RB> MAC$PBIUJ5C.^RB&/FX#^Y^VE%W<MVGD3PK3"-5MGZR>VX&)]%=.?W
M]4K=0Q08'M-&>9.D-2[';W!V?#KDC[!B9U/<+]NB^SW FO)$(G[-I_^>8X4V
MFCP?''6!Q=G AJ,JCTN_$L\-;XHX&BJ/?%9CZA_C=&<S.&3T:CA5=45$H@T^
M>661U[5]#-V;IW5IP</^@Z/@#/GA@WPN>+SKL"A"K7$TSC.*O7 RO$WY:.1D
M=KS;&)Q-9G<=M4#;HC7FRE[%54'WRB(@8GO0#ZJI@JO9GI9Z C"[]&+BJ_G8
MU4."*$KO#*+O#OUK;1\+] YM)]9,)]W?W?M)J 1@O>$_>X='@\/]/?KR^='@
MY=%^UXP/'# B5EHFFX#>\5T&J6FTWCBOP^9 5]TI]TRM_YV353KO-I_'@G3?
M_KI[);4[*,8@7J7^4KL]O5Y-GS#*J7(]TF,_WWUNZG3L[;W:%'V[KA9)B=,<
M,_3&FF5[*AD2OD.J4?D2.^J4!7F*:NE_UNG"H6Y%6;?W4AR546ZH@G6841*1
M4Y,\%\AY(B50I;YT6V)M6S6_GCP:FSR?4]&9I5E>=LM1! OM"=X!+24%V'>%
M[#9SK4))8;_Y/%WH[6RAY6#@S=='DO_0BW &4Q'L'0?ON0#>0C<PG:X=N&(Y
MB]WD(/5;U\S:?F/6G!I[07Z1)I=^JIU.:C^#9@8/CH,WZJ\2!=J6JB)VR'ZR
MS&0='F.AUEP@%2USI9[5?A]^[=0>':L.^&=L;ADRFW;0"PA2D".H%3IM2YC.
M<D)%Y#JFNI_9)751*I+\JXZ$;P#+G\C1QQL9)EO*HJE>1R57M0S@!.N82#B8
M4LC&^3QV5 :*7T4YW>WYP.4U4%= *7M_!G<8:V/U!2.5U-7NGB=*+\ZOB=9
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MC)$GP3.G+?SOSW_[V_\'4$L#!!0    ( .8S;5%F[R2HY P  -:$   1
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M)F ?B4Q0=14Z$'Z]BK"1UXV7& W_0(S(O07\@6.? *"Z]=WA9SP-S'3#7N0
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M]_.DY0-YDN^"R/ML(DG^%,.I-,^[;HYKW6@?F?5+$?U+@.>=A]?,ETW8>P3
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MKE0A!@0)$RJ1F6P.",<E5,B+)7"]]@K1RY2KCPZ)Z"24BN'2CH_WPK[08L'
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M47M=?3;EN!),";D>[!S,FR[%KIHXE04Y4J]KT::$&@*44.G!=O*W#($HA7^
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MLU4'5SV%Q2E],\VF\9?_ U!+ P04    " #F,VU1_IRK^GY'   0!P0 %0
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M-B,C&E:V9L+7> B(!+G1(63Z'D "W%79Y,WVNN2=Q]&=O]#+I$DN-E7%V4\
MT*:),R!MB(8'J.)*!FR)X$M:QM:0#24] ,+N*B"!V@H6S*W/D$!_SHTK$P;V
ML4B>)E ^^HTSK$>IA,=QSX8(/M:P!4L'P*E11"18CH\C,W0"\O3>+^TXYDWS
M_.BWX E_E!KBS*_X$<Y0N"7W(  LKT\T8!8:.3 8'_.1"$$##C3P?LSK-"G^
MC2;51_Z;V@#?B:_! )Z@APAAQ9$(ED3R= :QA\P^,+81'!G(4Z,_ F4M4)#!
MK,S('LXCWWL">H0B/J1;/^<#:J#< 6!M$#X*L,=P, GM2= @+>KNZ5,N-BW*
MYE.RFHHR=)\"%W'CQ- 6;SMV1/!S7+/!A86OU<P2HR[1)@;[:&FF P429"^X
ML51)<5UF]/5_TJT6LQ/? D$[00T-M2T_(AD2SM$1MQ[RPH%K(S0J=*?&_ B[
M6G @@?=C7M!/&W$2K,7M\6= R!X30D.K8$44+T><PH2$0U0O*2HX1P;V")=3
M@Q\<DNU&VBZHUF\VF#YW/S8R$$0X05(<]U8]SML.(<0&@-=1=JR3,!,(F'U'
MX88)BOD]7;.JR<NGSTW23*[<;)I @P8M4;S8H45+SY<HQJXAA+?T'I&$O0JX
M 84>%L=QA06,D$#_^9D6Q05;K9-2'QB/?0@$^!@I-%A+9J3EYHAEJ*!P!)ND
M187MZ! ?@74:"(@1<'7!9X$G5NDQ.OJE1QQ\1 LU%*Y(QPX0#8-$]0N(M?*B
MQ\3'XSP:%D_  <N;KI*B^+"I\Y+6^LAA]$NH/QVCA>=0!3?2L7/UJ%!1/5RJ
M25Y<GSHZSL=.=1H.2%"]6M'JB<<:/U3L2_-L$P%H6P"AJZ6)!N&.*U%L@=&!
MM^QP3-LK@ IN/2*.0&X!("RPOSY425GGXD*".C#1(WWR<RC,)PGB8?R5['BV
MQUJN />2V@/==J+C0GL: L>X-L %"=3G6<;[LKY@F[(Q!,;CGP+!/$X,#<@M
MNP5I&3J"&"XM', 6(J."=V*XCX"K@P4N:.]8W23%_\[7%RS3'R+K&O@!>)0D
M/HP56\+Y$L$8!F>P[ % ;58@!KC' 3$%<0U\@@/],TTW%6?]_MO'A[PIIN ]
M]9DSJ*<(A8>R)$_8DKS_]JO'KTG'V!K"/I("@&LO+A)@)X>8F?L$"9P\4A$7
MG#]O5X^LF$#FZ#?.L!RE@H!)Q88H/M90!$L'P:%)1"3XC8\C,W0"LE>\>DV?
M>>=03?:8[E.P=QPC%AZ-'3?2L7/+'O,5%@!.:XF1?>3H8(_XR6E08!T+L]6*
ME9\;EO[Z^3GA/7F[:61-"&XY^L-ABX;0(V(+TG@'Q9(YD=P71/$G P%<#XP#
MZ>)Q;.RN$.[QL0UPC@^1K>&&=[^XWP911]D3YF'Z''[O>((@8L[[8*-*\72_
MD.PAM-?E9 O)L6\J3P%@[-:R%BQH-YA35G%NLI*-R,J@[5Z)<=O"JB7X/K,%
M;33WO\=](3-L^"*KZO:Z()L:P10"V,-=E9=IODX*LBZ25"X7']MS. YEI1+_
M73X4,?[U9QLPC=R"ML8@[FY?^Y\;WJOO;3;[QK[WV^L;HXB_U=?^0 1;<EO.
MM54VVIU3.V73?1\^FUAPK6BB<:9CG[AG#8\00<@4ED//V43>%1WM(J;7'FE
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MQB +LB<?WH(ZWJ1C3KX:L"<M_[&%02Q]8 =[O0:9XAC7<AP PZ!]%S'AII-
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M: >,ABPH8X1(BJT<A0'C;A)R#)T"Z0!:WPT4R7;<8T=6-O@X"K>L084?@_U
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M-\$BKO%U"X>PUN>A6ESSZSK@),QP"G-V=JA%[+Q38'?(M3^5?V35DN;Z$Z,
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MU#SLK>M+6J=5OF[K WY(ZKR6+W?6W>6!!_K:?"CT!QEP8J ) ,XN/$X[6<A
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M>UP=S?6.D(QPST/$YGSU03.1"\SED![CMGM;]UKF2>0O5)SEF#,//*C![H#
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M@ 06HPL^U0T&+&MT];NH7N$$'+#]JF6FH-]1@KFW,4[7RX(V-TXIZ$?H9>3
M]F]I=V2.J!9D^Y&<ZJ-9K4?G8+U_3.""E4V5I,TF*<23 M^:'.P\TL"=[3SR
MGK;CU>^V[-X%&6CG_CK(B?=^B!!WNJ=,U4"P/?%,5CKFE>=T&*?OH:<GGBD5
MWR-Z: ]I9O'0'O*>MH?6A\8GXJ&1>Q_;0P_$_VUY:!\K#>RAO1U&A,=&9!8]
M9V9Z3&3L.]AC(6.4POL;E? M^$ *ZX.%!)BEC:28KY2,CNSA*R33PW\"FV>3
MFX,[L<OLCG?ZIV1%C67U,=E%/H4P"X1K>)"J_7-KZVG!LU3W1X5LL*UZ6_/
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M?J\11)ON0"[D!]!&Y4 N>DZT\11^X/G]='6JP]$##PD=CAA=>)T=]1.IOA=
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MFG$ORRP-"4UKGWZK@YF..UE;0=]CIS5B,9/WHL@Z:;?I!O-#<ELS4VU=M)T
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M[&8)TKT" G-(0SH'I(E7D#4%Y,AV^69YNBY'1D*TR@/ 1016*:#-_:]L#S1
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M^*B0!3N8/3#5K" =3@EU%8+U/D 8Y$/?,_\5"-MGWMG5X\GQ,7+<K-59;T2
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H8RTR,#(P,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  '9+ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
